IN, USA, 4Elilly and Company, Indianapolis, IN, USA, 5Institute of Medical ... WAITING LIST MORTALITY IMPACT IN HCV CIRR
Saturday Research Poster Presentations POSTER SESSION I: Poster Display Hours – 8:30 - 20:00 Poster Author Discussion Hour – 18:30 - 19:30
POSTER SESSION I: PRM: RESEARCH ON METHODS PMD: MEDICAL DEVICE/DIAGNOSTICS PCN: CANCER PGI: GASTROINTESTINAL DISORDERS PMH: MENTAL HEALTH PND: NEUROLOGICAL DISORDERS PRS: RESPIRATORY-RELATED DISORDERS PSY: SYSTEMIC DISORDERS/CONDITIONS PUK: URINARY/KIDNEY DISORDERS
ROWS A-B ROWS B-D ROWS D-H ROWS H ROWS H-I ROWS I-J ROWS J ROWS J-M ROWS M-N
1
2
Research Poster Presentations Acceptance Code PRM1-PRM3 PRM5-PRM9 PRM10-PRM16 PRM17-PRM19 PRM20 PRM21-PRM22 PRM23-PRM26
PDF Page # 4 4 4 5 5 5 5
Topic – Subtopic RESEARCH ON METHODS - Clinical Outcomes Methods RESEARCH ON METHODS - Cost Methods RESEARCH ON METHODS - Databases & Management Methods RESEARCH ON METHODS - Modeling Methods RESEARCH ON METHODS - Patient-Reported Outcomes Studies RESEARCH ON METHODS - Statistical Methods RESEARCH ON METHODS - Conceptual Papers
PMD1-PMD4 PMD5-PMD32 PMD33-PMD34
6 6 9
PMD35-PMD43
9
MEDICAL DEVICE/DIAGNOSTICS - Clinical Outcomes Studies MEDICAL DEVICE/DIAGNOSTICS - Cost Studies MEDICAL DEVICE/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies MEDICAL DEVICE/DIAGNOSTICS - Health Care Use & Policy Studies
PCN1-PCN12 PCN13-PCN37 PCN38-PCN39 PCN40-PCN63
10 10 13 13
CANCER - Clinical Outcomes Studies CANCER - Cost Studies CANCER - Patient-Reported Outcomes & Patient Preference Studies CANCER - Health Care Use & Policy Studies
PGI1-PGI5 PGI6-PGI9 PGI10
15 15 16
GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies GASTROINTESTINAL DISORDERS - Cost Studies GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies
PMH1-PMH5 PMH6-PMH11 PMH13
16 17 17
MENTAL HEALTH - Clinical Outcomes Studies MENTAL HEALTH - Cost Studies MENTAL HEALTH - Health Care Use & Policy Studies
PND1-PND3 PND4-PND5 PND6
17 17 18
PND7-PND9
18
NEUROLOGICAL DISORDERS - Clinical Outcomes Studies NEUROLOGICAL DISORDERS - Cost Studies NEUROLOGICAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies
PRS1-PRS3 PRS5-PRS10 PRS11-PRS13
18 18 19
RESPIRATORY-RELATED DISORDERS - Clinical Outcomes RESPIRATORY-RELATED DISORDERS - Cost Studies RESPIRATORY-RELATED DISORDERS - Patient-Reported Outcomes & Patient Preference Studies
PSY2-PSY10 PSY11-PSY31 PSY33-PSY43
19 20 22
PSY44-PSY48
23
SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies SYSTEMIC DISORDERS/CONDITIONS - Cost Studies SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient Preference Studies SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies
PUK1-PUK2 PUK3-PUK6 PUK7-PUK9
24 24 24
PUK10-PUK11
25
URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies URINARY/KIDNEY DISORDERS - Cost Studies URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes & Patient Preference Studies URINARY/KIDNEY DISORDERS - Health Care Use & Policy Studies
3
RESEARCH POSTER PRESENTATIONS SESSION I RESEARCH ON METHODS STUDIES RESEARCH ON METHODS - Clinical Outcomes Methods PRM1 A1
PRM2 A2
PRM3 A3
CELEBRITY DEATHMATCH: BURDEN OF DISEASE VS RCTS IN THE SOUTHERN CONE OF LATIN AMERICA Bardach A1, Belizan J2, Glujovsky D3, Ciapponi A4,1National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina, 2National Scientific and Technical Research Council (CONICET), CABA, Argentina, 3Institute for Clinical Effectiveness and Health Policy, CABA, Argentina, 4Cochrane Center Argentina, CABA, Argentina IMPACTO ECONÓMICO DIRECTO DERIVADO DE LA ATENCIÓN DE PACIENTES TRAUMATIZADOS EN UN HOSPITAL DE MÉXICO. Medina Tirado MA1, Contreras Hernandez I2, Garcia Canseco AG1, Huerta Garcia de Leon O1, Gomez Montoya LE1, Hernandez Rosas AI1,1Instituto Salud de Estado de Mexico, Zitacuaro, Mexico, 2Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico INVESTIGATION OF DRUG THERAPY PROBLEMS IN TYPE 2 DIABETES OUTPATIENTS WITH COMORBID HYPERTENSION IN A TERTIARY HOSPITAL IN SOUTHEAST NIGERIA Ogbonna B, Amagba C,Nnamdi Azikiwe University Awka, Awka, Nigeria
RESEARCH ON METHODS - Cost Methods PRM5 A5
PRM6 A6
PRM7 A7
PRM8 A8
PRM9 A9
COST-EFFECTIVENESS THRESHOLD IN BRAZIL THROUGH A LEAGUE-TABLE APPROACH: SYSTEMATIC REVIEW Ribeiro RA1, Neyeloff JL2, Marcolino MA3, Falcetta FS3, Hauck M3, Plentz RD3, Polanczyk CA2,1UFCSPA, IATS & HTAnalyze, Porto Alegre, Brazil, 2Hospital de Clínicas de Porto Alegre and IATS, Porto Alegre, Brazil, 3Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil COSTO-EFECTIVIDAD DEL TRATAMIENTO DE LA ARTRITIS REUMATOIDE (AR) TEMPRANA: UNA REVISIÓN SISTEMÁTICA. Diaz JA1, Huerfano CR1, Brown P2,1Universidad Nacional de Colombia, Bogotá D.C., Colombia, 2University of California, Merced, Merced, CA, USA COST-EFFECTIVENESS THRESHOLDS: REVIEW OF METHODS Santos AS1, Guerra-Junior Aa2, Brandão CM1,1Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 2SUS Collaborating Centre - CCATES - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil FACTORS ASSOCIATED WITH THE PREVALENCE OF TIME IN FRONT OF TV BETWEEN BRAZILIAN SCHOOLERS (2012 AND 2015) Margarido OT, Machado FF, Costa CK, Cunha MS,E ESTADUAL DE MARINGÁ, MARINGÁ, Brazil EVALUATION OF THE COST EFFECTIVENESS OF THE TREATMENT OF MILD AND MODERATE ALZHEIMER’S DISEASE Langsch LR,Universidade do Estado do Rio de Janeiro, São Pedro da Aldeia, Brazil
RESEARCH ON METHODS - Databases & Management Methods PRM10 A10 SELEÇÃO SISTEMÁTICA DE COORTES EM BASES DE DADOS ASSISTENCIAIS Abrahão MT1, Nobre MR2, Gutierrez MA1,1Universidade de São Paulo - HCFMUSP, São Paulo, Brazil, 2Sao Paulo University, Sao Paulo, Brazil PRM11 A11 ANÁLISE DE SIGNIFICÂNCIA DO BANCO DE DADOS DA SAÚDE SUPLEMENTAR – SS NO BRASIL, SOB AS PERSPECTIVAS DOS ATENDIMENTOS EM HOSPITAIS E DEMAIS PRESTADORES PARTICULARES Rodrigues SR1, Paiva EC2, Paloni Ed2, Rocha ML2, Neto LA2,1Universidade de São Paulo, São Paulo, Brazil, 2Orizon, Barueri, Brazil PRM12 A12 BIBLIOMETRIC ANALYSIS OF THE WORLDWIDE RESEARCH PRODUCTIVITY ON ORAL HEALTH RELATED QUALITY OF LIFE (OHRQL)
4
PRM13 A13
PRM14 A14
PRM15 A15
PRM16 A16
Hernández-Vásquez A1, Huarez B2, Azañedo D3,1Universidad Privada del Norte, Lima, Peru, 2Instituto Nacional de Salud, Lima, Peru, 3Centro de Estudios de Población, Universidad Católica los Ángeles de Chimbote, Chimbote, Peru ASSESSING COMPARABILITY AND PATIENT PROFILE OF TWO CLAIMS DATABASES IN ONCOLOGY IN BRAZIL Julian GS, Saad R, de Oliveira RW, Moreira Ed,Evidências - Kantar Health, São Paulo, Brazil WORLDWIDE RESEARCH PRODUCTIVITY ON BIOSIMILARS: A BIBLIOMETRIC ANALYSIS Hernández-Vásquez A1, Díaz-Seijas D2,1Universidad Privada del Norte, Lima, Peru, 2Instituto Nacional Cardiovascular-INCOR- EsSalud, Lima, Peru VALIDAÇÃO DO MÉTODO SIMPLE EXPONENTIAL SMOOTHING WITH ADDITIVE PARA REALIZAÇÃO DE PREVISÕES DE GASTO COM IMPORTAÇÃO DE PRODUTOS FARMACÊUTICOS Bernuci MP1, Buzeti L2, Bortolozzi F3, Almeida IC4,1UniCesumar-ICETI, Maringa, Brazil, 2UniCesumar, Maringa, Brazil, 3UniCesumar/ICETI, Maringa, Brazil, 4UniCesumar/ICETI, Maringá, Brazil COST OF ACUTE MYOCARDIAL INFARCTION IN COLOMBIA (2014) Dávila FA, Barajas FD, Valenzuela E,Sanofi, Bogotá, Colombia
RESEARCH ON METHODS - Modeling Methods PRM17 A17 SYSTEMATIC REVIEW OF MARKOV MODEL-BASED ECONOMIC EVALUATION STUDIES FOR CERVICAL CANCER SCREENING STRATEGIES: LATIN AMERICA COUNTRIES PANORAMA Viscondi JY1, Faustino CG1, Campolina AG2, De Soárez PC1,1University of Sao Paulo, Sao Paulo, Brazil, 2Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil PRM18 A18 CRISES ECONÔMICAS E SEUS IMPACTOS NO SISTEMA DE SAÚDE DO BRASIL Ramires Y1, Ferreira VL1, Sousa FM2, Klingelfus BL2, Oliveira K2, Gajardo PD2,1Universidade Federal do Paraná, Curitiba, Brazil, 2Unimed Curitiba, Curitiba, Brazil PRM19 B1 MODELO ECONÓMICO DE ESTIMACIÓN DE GASTO FARMACÉUTICO EN UNA ASEGURADORA COLOMBIANA Romero Prada ME1, Vivas Consuelo D2, Marino C3, Gallo D4, Celis S5,1Fundación Salutia, Bogotá, Colombia, 2Universitat Politècnica de València, Valencia, Spain, 3Coomeva, Bogotá, Colombia, 4Salutia Foundation- Research center in economy, management and health technologies., Bogota, Colombia, 5Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia RESEARCH ON METHODS - Patient-Reported Outcomes Studies PRM20 B2
USO DE LOS ÍNDICES DE SHANNON EN LA EVALUACIÓN DEL PODER DISCRIMINANTE DEL EQ-5D Y EL EQ-5D-5L EN UNA MUESTRA DE PACIENTES CON VIH/SIDA EN COLOMBIA. Muñoz-Galindo IM1, Diaz JA2, Guarin NE1, Arevalo HO1, Hoyos-Beltrán FJ1, Moreno JA1,1Salud Total EPS, Bogotá D.C., Colombia, 2Universidad Nacional de Colombia, Bogotá D.C., Colombia
RESEARCH ON METHODS - Statistical Methods PRM21 B3
PRM22 B4
DETERMINANTES DO ATRASO ESCOLAR E DA OBESIDADE NOS ADOLESCENTES BRASILEIROS (2012 E 2015) Favro J1, Marconato M1, Costa CK1, Cunha MS2,1E ESTADUAL DE MARINGA, Maringá, PR, Brazil, 2E ESTADUAL DE MARINGÁ, MARINGÁ, Brazil CHARACTERIZATION OF WORLDWIDE PUBLICATIONS ON NETWORK META-ANALYSIS: A SYSTEMATIC REVIEW Tonin FS1, Borba HH1, Steimbach LM1, Mendes AM1, Fernandez-Llimos F2, Pontarolo R1,1Federal University of Parana, Curitiba, Brazil, 2University of Lisboa, Lisboa, Portugal
RESEARCH ON METHODS - Conceptual Papers PRM23 B5
PRM24 B6
OPPORTUNITY COST OF NON-RIGOROUS OR NON-TRANSFERABLE RESEARCH: IMPLICATIONS FOR COST-EFFECTIVENESS ANALYSIS Alarid-Escudero F1, Jalal H2, Trikalinos TA3,1University of Minnesota, Minneapolis, MN, USA, 2University of Pittsburgh, Pittsburgh, PA, USA, 3Brown University, Providence, RI, USA OVERALL SURVIVAL (OS) VERSUS PROGRESSION-FREE SURVIVAL (PFS): IS THERE A RATIONAL FOR REPLACING ONE OUTCOME FOR THE OTHER?
5
PRM25 B7
PRM26 B8
Teich V1, Fernandes RA2,1Sense Company, São Paulo, Brazil, 2Sense Company, Rio de Janeiro, Brazil BUDGET IMPACT ANALYSIS OF VACCINES: WHAT ARE THE METHODOLOGICAL ISSUES? De Soarez PC1, Sartori AM2, Leandro RF3, Silva DR3, Soarez DS3, Campolina AG3, Novaes HM4,1Universidade de São Paulo, São Paulo, Brazil, 2Universidade de Sao Paulo, São Paulo, Brazil, 3University of São Paulo, São Paulo, Brazil, 4Universidade de São Paulo, Sao Paulo, Brazil MODEL ATTENTION IMPROVE THE HOSPITAL NUTRITION PROCESSES UNDER THE CENTER OF EXCELLENCE CONCEPT Valencia CF1, Pinzon Espitia OL2, Lopez Gutierrez PA3, Pombo L3,1Javeriana University / OES, Bogotá DC, Colombia, 2National University of Colombia / Méderi, Bogotá DC, Colombia, 3OES, Bogotá DC, Colombia
SELECTED HEALTH CARE TREATMENT STUDIES MEDICAL DEVICE/DIAGNOSTICS - Clinical Outcomes Studies PMD1 B9
PMD2 B10
PMD3 B11
PMD4 B12
MULTIPATHOGEN DETECTION METHODS FOR L. MONOCYTOGENES IN FOOD SAMPLE: A SYSTEMATIC REVIEW. Souza VR1, Ferreira VL2, Pasquini-Netto H1, Fernandez-Llimos F3, Pontarolo R1,1Federal University of Parana, Curitiba, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3University of Lisboa, Lisboa, Portugal ECOCARDIOGRAMA SOB ESTRESSE COM DOBUTAMINA: ALTERNATIVA ECONÔMICA E EXEQÜÍVEL NA AVALIAÇÃO DE RISCO CARDIOVASCULAR PRÉ TRANSPLANTE RENAL Pontes SC1, Coelho PR2, Chaoubah A3, Castro Jr. JR1, Colares VS4, Ferreira GF2,1Universidade Federal de Juiz de Fora e Santa Casa de Misericordia de Juiz de Fora, Juiz de Fora, Brazil, 2Santa Casa de Misericordia de Juiz de Fora, Juiz de Fora, Brazil, 3Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, 4Universidade Federal de Juiz de Fora e Santa Casa de Misericordia de Juiz de Fora, Juiz de Fora, Brazil DEEP BRAIN STIMULATION FOR PARKINSON'S DISEASE: COMPARISON BETWEEN UNILATERAL AND BILATERAL IMPLANTATION. Bustorff-Silva JM, Psaltikidis EM, Militão L, Resende MR, Passeri LA,University of Campinas, Campinas - SP, Brazil DRY-WEIGHT ASSESSMENT AMONG HEMODIALYSIS PATIENTS USING BODY COMPOSITION MONITOR Khan A1, Khan AH1, Adnan AS2, Sulaiman SA2, Khan I3,1Universiti Sains Malaysia, Pulau Pinang, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 3Univesiti Sains Malaysia, Penang, Malaysia
MEDICAL DEVICE/DIAGNOSTICS - Cost Studies PMD5 B13
PMD6 B14
PMD7 B15
PMD8 B16
PMD9 B17
ANÁLISIS DE IMPACTO PRESUPUESTARIO COMPARANDO 2 MÉTODOS DE SCREENING DE CÁNCER DE CUELLO UTERINO (CCU) EN EL SECTOR DE OBRAS SOCIALES DE ARGENTINA Roa R1, Jorgensen N2, Denamiel JP1,1Universidad ISALUD, Buenos Aires, Argentina, 2Superintendencia de Servicios de Salud (SSS), Buenos Aires, Argentina ECONOMIC BENEFITS OF SFLT-1/PLGF TESTING FOR PREECLAMPSIA IN COLOMBIA: A FIVER YEAR BUDGET IMPACT ANALYSIS Duva AS1, Rosim RP1, Ballalai Ferraz AF1, Cachoeira C2, Mojica IL3,1QuintilesIMS, São Paulo, Brazil, 2Roche Brazil, São Paulo, Brazil, 3Roche Colombia, Bogota, Colombia BUDGET IMPACT MODEL OF POINT OF CARE TEST FOR PATIENTS UNDER CHRONIC WARFARIN THERAPY IN BRAZIL Costa T1, Carvalho JP2, D'Innocenzo M2, Figueira SF2,1Roche Diagnostics Latin America, São Paulo, Brazil, 2Roche Diagnostics Brazil, São Paulo, Brazil ANÁLISIS DE IMPACTO PRESUPUESTARIO COMPARANDO 2 MÉTODOS DE SCREENING DE CÁNCER DE CUELLO UTERINO EN EL SECTOR PÚBLICO DE ARGENTINA Lifschitz E1, Tatti SA1, Fleider L1, Simonovich VA2,1Facultad de Medicina, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina, 2Hospital Italiano de Buenos Aires, Buenos Aires, Argentina ANÁLISIS DE IMPACTO PRESUPUESTARIO COMPARANDO 2 MÉTODOS DE SCREENING DE CÁNCER DE CUELLO UTERINO (CCU) EN EL SECTOR PRIVADO DE ARGENTINA Roa R1, Jorgensen N2, Denamiel JP1,1Universidad ISALUD, Buenos Aires, Argentina, 2Superintendencia de Servicios de Salud (SSS), Buenos Aires, Argentina
6
PMD10 B18
SENSOR AUGMENTED PUM VS MULTIPLE DAILY INJECTIONS IN VERY UNCONTROLLED DIABETES PATIENTS: COST MODEL FOR HYPOGLYCEMIC EVENTS, IMSS PERSPECTIVE Cerezo O1, Gasca R1, Valencia J2,1Medtronic, MX, Mexico, 2Medtronic, Miami, FL, USA PMD11 C1 GREAT SAPHENOUS VEIN RADIOFREQUENCY ABLATION VERSUS STANDARD STRIPPING IN THE MANAGEMENT OF PRIMARY VARICOSE VEINS: ECONOMIC EVALUATION INTO THE MEXICAN CONTEXT. Cerezo O1, Valls M2, Gonzalez Godinez I2, Valencia J3, Gay Molina JG2,1Medtronic, MX, Mexico, 2T.I. Salud, Mexico D.F., Mexico, 3Medtronic, Miami, FL, USA PMD13 C2 ECONOMIC ASSESSMENT OF NT-PROBNP TEST FOR ACUTE HEART FAILURE AT BRAZILIAN PRIVATE PAYER PERSPECTIVE Carvalho JP, D'Innocenzo M, Figueira SF,Roche Diagnostics Brazil, São Paulo, Brazil PMD14 C3 COMPARISON OF CATHETER ABLATION VERSUS MEDICAL TREATMENT FOR PAROXYSMAL ATRIAL FIBRILLATION: HEALTHCARE UTILIZATION AND COSTS ANALYSIS (PRELIMINARY RESULTS) Oliveira D1, Oliveira FM1, Luque A2, Junqueira Junior SM1,1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson&Johnson Medical Brazil, Sao Paulo, Brazil PMD15 C4 ESTIMATIONS OF RESOURCE USE, COSTS, CLINICAL AND EPIDEMIOLOGICAL OUTCOMES OF CONTINUOUS AND INTERMITTENT RENAL REPLACEMENT THERAPIES Garay OU1, Palacios A1, Tapia-Lopez E1, Hernández-Vásquez A1, Garcia Marti S1, Pichon-Riviere A1, Augustovski F2, Bardach A3,1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Argentina, 3National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina PMD16 C5 COST ASSOCIATED WITH BALLON-EXPANDABLE VALVE VS SELF-EXPANDABLE VALVES IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT Ferreira CN1, Paloni Ed2, Rodrigues SR3, Brunet VA2,1Edwards Lifesciences Latam, São Paulo, Brazil, 2Orizon, Barueri, Brazil, 3Universidade de São Paulo, São Paulo, Brazil PMD17 C6 BURDEN DISEASE OF AORTIC STENOSIS ASSOCIATED IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT Ferreira CN1, Paloni Ed2, Rodriguez SR2, Brunet VA2,1Edwards Lifesciences Latam, São Paulo, Brazil, 2Orizon, Barueri, Brazil PMD18 C7 ESTIMACIÓN DE COSTOS DE LOS SERVICIOS DE HEMODIÁLISIS CRÓNICA Y HEMODIAFILTRACIÓN EN ARGENTINA Palacios A, Mengarelli C, Augustovski F,Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina PMD19 C8 ENHANCED SURGICAL RECOVERY PROGRAM PERIOPERATIVE GOAL DIRECTED THERAPY (PGDT) ECONOMIC BENEFIT Okumura LM1, Riveros BS2, Lucchetta RC2, Rosim MP3, Nita ME4, Goodall G5, Ferreira CN6,1Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Universidade de São Paulo, São Paulo, Brazil, 4Market Access and Patient Engagement Solutions - MAPES, São Paulo, Brazil, 5Edwards Lifesciences SA, Nyon, Switzerland, 6Edwards Lifesciences Latam, São Paulo, Brazil PMD20 C9 DIRECT COSTS OF LONG-TERM PSYCHIATRIC HOSPITALIZATION IN PUBLIC HOSPITAL OF THE STATE OF SAO PAULO, BRAZIL: THE COMPLEXO HOSPITALAR JUQUERY CASE Siomi AB, Razzouk D,Universidade Federal de São Paulo, São Paulo, Brazil PMD21 C10 COST ASSOCIATED WITH SELF-EXPANDABLE VALVES IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT IN LATIN AMERICA Okumura LM1, Riveros BS2, Lucchetta RC2, Rosim MP3, Nita ME4, Ferreira CN5,1Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Universidade de São Paulo, São Paulo, Brazil, 4Market Access and Patient Engagement Solutions - MAPES, São Paulo, Brazil, 5Edwards Lifesciences Latam, São Paulo, Brazil PMD22 C11 HEMODYNAMIC MONITORING CAN REDUCE COSTS ON HIGH RISK PATIENTS WHO UNDERWENT LARGE/MEDIUM SURGICAL PROCEDURES Fahham L1, Pepe C1, Ferreira CN2,1SENSE Company, São Paulo, Brazil, 2Edwards Lifesciences Latam, São Paulo, Brazil
7
PMD23 C12 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS VERSUS INTERMITTENT RENAL REPLACEMENT THERAPY FOR CRITICALLY ILL ACUTE KIDNEY INJURY PATIENTS UNDER THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM. Ramirez MG1, Costa MD2, Costa Carvalho M3,1Baxter, Mexico city, Mexico, 2Baxter, Sao Paulo, Brazil, 3FMUSP, Sao Paulo, Brazil PMD24 C13 COST-EFFECTIVENESS STUDY OF THE USE OF PORTABLE COAGULOMETERS FOR THE INR CONTROL, IN COMPARISON WITH HOSPITAL CARE, IN PATIENTS WITH COAGULATION DISORDERS, UNDER THE CONTEXT OF THE MEXICAN PUBLIC HEALTH SETTING. Bautista J1, Reyes-Loredo J2, Cachoeira C3, Gay Molina JG4,1Roche Diagnostics Mexico, Ciudad de México, Mexico, 2Roche, Mexico, Mexico, 3Roche Brazil, São Paulo, Brazil, 4T.I. Salud, Mexico D.F., Mexico PMD25 C14 SEAL OR VARNISH? COST-EFFECTIVENESS OF FISSURE SEALANTS VERSUS FLUORIDE VARNISH IN PREVENTING DENTAL DECAY IN CHILDREN Humphreys I1, Chestnut I2, Fitzsimmons D3,1Swansea University, Swansea, UK, 2Cardiff University, Cardiff, UK, 3Swansea Uiniversity, Swansea, UK PMD26 C15 COST-EFFECTIVENESS OF LIDOCAINE MEDICATED PATCH COMPARED WITH PREGABALIN AND GABAPENTIN FOR THE TREATMENT OF POSTHERPETIC NEURALGIA AN DIABETIC POLYNEUROPATHY IN COLOMBIA Acosta A1, Rueda MC1, Castañeda-Cardona C2, Gil-Rojas Y1, Rosselli D3,1Pontificia Universidad Javeriana, Bogota, Colombia, 2NeuroEconomix, Bogota, Colombia, 3Pontificia Universidad Javeriana, Bogotá, Colombia PMD27 C16 A MINIMALLY INVASIVE HEMODYNAMIC MONITORING DEVICE FOR THE BRAZILIAN HEALTH SYSTEM: IS FLOTRAC® COST-EFFECTIVE? Okumura LM1, Riveros BS2, Lucchetta RC2, Rosim MP3, Nita ME4, Goodall G5, Ferreira CN6,1Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Universidade de São Paulo, São Paulo, Brazil, 4Market Access and Patient Engagement Solutions - MAPES, São Paulo, Brazil, 5Edwards Lifesciences SA, Nyon, Switzerland, 6Edwards Lifesciences Latam, São Paulo, Brazil PMD28 C17 COST-EFFECTIVENESS ANALYSIS OF A KNEE IMPLANTS STANDARDIZATION MODEL IN TERTIARY HOSPITALS Luque A1, Oliveira FM2, Junqueira Junior SM2, Oliveira D2, Cabra HA3,1Johnson&Johnson Medical Brazil, Sao Paulo, Brazil, 2Johnson & Johnson Medical Brazil, São Paulo, Brazil, 3Johnson & Johnson Medical, Miami, FL, USA PMD29 C18 INCONTINENCE CONTROL SYSTEM (INTERSTIM®) FOR THE FECAL INCONTINENCE TREATMENT AT HEALTHCARE PUBLIC SECTOR IN MEXICO Cerezo O1, Orozco D2, Saracho A2, Lemus F2, Flores B2, Valencia J3, Figueroa A2,1Medtronic, MX, Mexico, 2Pharmamanagement EAS S de RL de CV, Cuidad de México, Mexico, 3Medtronic, Miami, FL, USA PMD30 D1 ECONOMIC EVALUATION OF DIALYSIS DEPENDENCE FOLLOWING RENAL REPLACEMENT THERAPY FOR CRITICALLY ILL ACUTE KIDNEY INJURY PATIENTS Ariza JG1, Barrera L2, Sanabria M3, Echeverri J3, Huerfano M3, Arboleda A3, Bunch A4, Garcia JC5, Vesga J3, Larrarte C4,1BAXTER, BOGOTA, Colombia, 2 DE LA SABANA, BOGOTÁ, Colombia, 3RTS, Bogota, Colombia, 4Renal Therapy Services, BOGOTA, Colombia, 5Universidad de la Sabana, BOGOTÁ, Colombia PMD31 D2 POTENCIALES AHORROS DE LA IMPLEMENTACIÓN DE LA PRUEBA DÍMERO D (POINT OF CARE) EN LA ATENCIÓN DE PRIMER CONTACTO DE PACIENTES CON SOSPECHA DE TROMBOSIS VENOSA. Contreras I1, Mendez G2, Quevedo CS3,1Instituto Mexicano del Seguro Social, Mexico D.F., Mexico, 2Instituto Mexicano del Seguro Social, Xalapa, Mexico, 3Instituto Mexicano del Seguro Social, Mexico, Mexico PMD32 D3 ANÁLISIS MULTICRITERIO DEL USO DE DOS LÍQUIDOS DIALIZANTES PARA HEMODIÁLISIS EN PERÚ Bolaños-Díaz R1, Tejada RA1, Sanabria C2, Paredes-Alfaro F3,1Instituto Nacional de Salud, Lima, Peru, 2Universidad Nacional Mayor de San Marcos, Lima, Peru, 3Universidad Nacional Federico Villarreal, Lima, Peru
8
MEDICAL DEVICE/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies PMD33 D4
PMD34 D5
A DISCRETE CHOICE EXPERIMENT TO ELICIT DIABETES TREATMENT PREFERENCES AMONG ADOLESCENTS WITH TYPE 1 IN WESTERN AUSTRALIA Barnett N1, Geelhoed E1, Davis E2, Jones TW 2, De Bock M2, Norman R3,1The University of Western Australia, Perth, Australia, 2Princess Margaret Hospital for Children, Subiaco WA, Australia, 3Curtin University, Perth, Australia CAMBIOS EN LA CALIDAD DE VIDA RELACIONADA CON LA SALUD DE PACIENTES SOMETIDOS A PREPARACIÓN INTESTINAL Romero Prada ME1, Albanes Beltran JP2, Huerfano LM3, Cardoso N4, Bermeo Y4,1Coomeva EPS, Bogotá, Colombia, 2Universidad Nacional de Colombia, Bogotá, Colombia, 3Fundación Salutia, Bogotá, Colombia, 4Centro de Diagnóstico, Bogota, Colombia
MEDICAL DEVICE/DIAGNOSTICS - Health Care Use & Policy Studies PMD35 D6
SPIROMETRY OF LUNG FUNCTION EVALUATION IN STONE CRUSHING WORKERS QUETTA, PAKISTAN. Ahmed T1, Hanif M1, Iqbal Q1, Minhas M1, Sarwar G1, Mehmood S2,1University of Balochistan, Quetta, Pakistan, 2Bolan Medical Complex Hospital, Quetta, Pakistan PMD36 D7 OUTCOMES IN CONTACT FORCE TECHNOLOGY USE FOR CARDIAC ABLATION – ROLE OF PROCEDURE VOLUME Khanna R1, Kalsekar I1, Barnow A2, Liao R3,1Johnson & Johnson Co., New Brunswick, NJ, USA, 2Johnson & Johnson, Diamond Bar, CA, USA, 3Janssen R&D US, Raritan, NJ, USA PMD37 D8 TITLE: MODELLING THE EFFECT OF SYPHILIS SCREENING AT THE ENTRY POINT IN CHILEAN PRISONS Castillo-Laborde C1, Najera-De Ferrari M1, Gajardo P2, Aguirre P2, Ramírez H3, Ramírez D2, Cesped A1, Aguilera X1, González C1, Hirmas M1, Matute I1, Olea A1, Delgado I1,1Universidad del Desarrollo, Santiago, Chile, 2Universidad Técnica Federico Santa María, Valparaiso, Chile, 3Universidad de Chile, Santiago, Chile PMD38 D9 BARRERAS Y FACILITADORES PARA LA COBERTURA DE PERITONEODIÁLISIS EN CHILE Espinoza MA1, Bernales M2, McIntyre AM2,1e Investigador Visitante Honorario, Centro para la Economía de Salud, Universidad de York, York, UK, 2Universidad del Desarrollo, Santiago, Chile PMD39 D10 MEJORAMIENTO DE LOS RESULTADOS CLÍNICOS EN PACIENTES CON REEMPLAZOS DE CADERA Y RODILLA Serna ID1, Mejía LA1, Nunez CE2,1Clinica El Rosario, Medellin, Colombia, 2Johnson & Johnson Medical, Bogota, Colombia PMD40 D11 SYSTEMATIC REVIEW ON CLINICAL OUTCOMES OF ULTRASONIC TECHNOLOGY FOR PATIENTS UNDERGOING GYN ONCOLOGY PROCEDURES Chen BP1, Goldstein LJ2, Alder H3, Brown J3, Cheng H4,1Thomas Jefferson University, Philadelphia, PA, USA, 2Johnson & Johnson, Markham, ON, Canada, 3ACCESS TO CARE PARTNERS LLC, Chicago, IL, USA, 4Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA PMD41 D12 EFFECTIVENESS OF THE PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER IN ADULT AND PEDIATRIC PATIENTS Dantas SR1, Fagnani R1, Lima TC1, Silva VA1, Azevedo MO1, Bueno GC1, Gadanhoto AP1, Oliveira AP2, Psaltikidis EM1, Carrara D3, Resende MR4,1Clinical Hospital of State University of Campinas, Campinas, Brazil, 2Faculty of Medical Sciences of State University of Campinas, Campinas, Brazil, 3Heart Institute - Medical School of the University of São Paulo, São Paulo, Brazil, 4Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil PMD42 D13 EFFECTIVENESS OF SURGICAL STABILIZATION OF RIB FRACTURES WITH OR WITHOUT FLAIL CHEST – A SYSTEMATIC REVIEW Oliveira FM1, Junqueira Junior SM1, Oliveira D1, Luque A2, Cabra HA3,1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson&Johnson Medical Brazil, Sao Paulo, Brazil, 3Johnson & Johnson Medical, Miami, FL, USA PMD43 D14 ROBOTIC ONCOLOGICAL SURGERY PROGRAM EVALUATION USING A LOGIC MODEL Kobayashi ST1, Campolina AG2, Zaidan EP1, Abdalla RZ1, Ribeiro Jr U1, Novaes HM3, Cecconello I4,1Instituto do Cancer do Estado de Sao Paulo - Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, 2Cancer Institute of the State of Sao Paulo, Sao Paulo,
9
Brazil, 3Universidade de São Paulo, Sao Paulo, Brazil, 4Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil DISEASE- SPECIFIC STUDIES CANCER - Clinical Outcomes Studies PCN1 D15
PCN2 D16
PCN3 D17
PCN4 D18
PCN7 E1
PCN8 E2
PCN9 E3
PCN10 E4
PCN11 E5
PCN12 E6
ADDING RAMUCIRUMAB TO SECOND-LINE IRINOTECAN, 5-FLUOROURACIL AND FOLINIC ACID (FOLFIRI) TREATMENT FOR METASTATIC COLORECTAL CARCINOMA (MCRC): RESOURCE UTILIZATION DATA FROM RAISE, A GLOBAL, RANDOMIZED, DOUBLE-BLIND, MULTICENTER PHASE 3 STUDY Brück P1, Kisro J2, Cohn AL3, Yoshino T4, Van Cutsem E5, Hegewisch-Becker S6, Kullmann F7, Liepa AM8, Yang L9, Nasroulah F9, Tabernero J10,1Lilly Deutschland GmbH, Bad Homburg, Germany, 2Onkologisches Zentrum Lübeck e.V, Lübeck, Germany, 3Rocky Mountain Cancer Center/US Oncology, Denver, CO, USA, 4National Cancer Center Hospital East, Chiba, Japan, 5University Hospitals Gasthuisberg, Leuven, Belgium, 6Hematological/Oncological Practice, Hamburg, Germany, 7Klinikum Weiden, Weiden, Germany, 8Eli Lilly and Company, Indianapolis, IN, USA, 9Eli Lilly and Company, Bridgewater, NJ, USA, 10Vall d'Hebron University Hospital, Barcelona, Spain EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER Zhou K,Sichuan University, Chengdu, China INTRACORPOREAL VERSUS EXTRACORPOREAL ANASTOMOSIS IN LAPAROSCOPIC RIGHT HEMICOLECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS Oliveira D1, Luque A2, Oliveira FM1, Junqueira Junior SM1,1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson&Johnson Medical Brazil, Sao Paulo, Brazil ANÁLISE DA QUALIDADE DA EVIDÊNCIA CIENTÍFICA ENTRE XELOX E FOLFOX NO TRATAMENTO DO CÂNCER COLORRETAL Boscato SC1, Godoy MR2, Heineck I1,1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Instituto de Avaliação de Tecnologia em Saúde - IATS, Porto Alegre, Brazil CETUXIMAB IN THE TREATMENT OF MCRC LIVER LIMITED DISEASE: A SYSTEMATIC REVIEW Correa Jd1, Amaral LM2, Biglia LV3, Souza PV3, Blum RR3,1SENSE Company, Rio de Janeiro, Brazil, 2Sense Company, Rio de Janeiro, Brazil, 3Merck, São Paulo, Brazil EVALUATING ACCESS TO TREATMENT: A COMPARISON OF THE EXPECTED NUMBER OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TO THOSE EFFECTIVELY TREATED IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM Kim HS, Fahham L,SENSE Company, São Paulo, Brazil MULTIPLE MYELOMA: EPIDEMIOLOGY AND BURDEN OF DISEASE ANALYSIS IN LATIN AMERICA Pineli M1, Pinho W 1, Amigo C2, Alvarado CA3, Figueroa R4, Bucheli E5,1Takeda Pharmaceuticals Brazil, São Paulo, Brazil, 2Takeda Pharma S.A., Buenos Aires, Argentina, 3Takeda Colombia, Bogotá, Colombia, 4Takeda México S.A de C.V, Naucalpan, Mexico, 5Takeda Ecuador Cía. Ltda., Quito, Ecuador PATIENT AND TUMOR PROFILES IN THE BRAZILIAN PRIVATE SETTING: DATA FROM THE AUDITRON CLAIMS DATABASE Julian GS, Saad R, de Oliveira RW, Moreira Ed,Evidências - Kantar Health, São Paulo, Brazil ANALYZING OVARIAN CANCER RECURRENCE AFTER TUMOR RESECTION IN OTHER SITES THROUGH THE BRAZILIAN PUBLIC HEALTHCARE CLAIM DATABASES (DATASUS) Rosim RP, Campos DF, Duva AS, Hirth WA, Ballalai Ferraz AF,QuintilesIMS, São Paulo, Brazil EFECTO DEL 1B8 EN EL TRATAMIENTO DE PACIENTES CON LINFOMA NO HODGKIN CD20+ Saumell Nápoles Y,Institute of Molecular Immunology, Havana, Cuba
CANCER - Cost Studies PCN13 E7
ANÁLISE DE IMPACTO ORÇAMENTÁRIO DO AXITINIBE NA SEGUNDA LINHA DE TRATAMENTO DO CARCINOMA DE CÉLULAS RENAIS METASTÁTICO SOB A PERSPECTIVA DO SISTEMA PRIVADO DE SAÚDE BRASILEIRO Alexandre RF, Squiassi HB, Santana CF,Pfizer, São Paulo, Brazil
10
PCN14 E8
PCN15 E9
PCN16 E10
PCN17 E11
PCN18 E12
PCN19 E13
PCN20 E14
PCN21 E15
PCN22 E16
PCN23 E17
PCN24 E18
PCN25 F1
ANÁLISE DE IMPACTO ORÇAMENTÁRIO DO CRIZOTINIBE NO TRATAMENTO DO CÂNCER DE PULMÃO NÃO PEQUENAS CÉLULAS AVANÇADO ALK-POSITIVO SOB A PERSPECTIVA DO SISTEMA PRIVADO DE SAÚDE BRASILEIRO Alexandre RF, Squiassi HB, Santana CF,Pfizer, São Paulo, Brazil ANTECIPAÇÃO AO ROL DE PROCEDIMENTOS DA AGÊNCIA NACIONAL DE SAÚDE SUPLEMENTAR: IMPACTO ORÇAMENTÁRIO DA INCORPORAÇÃO DE UM NOVO INIBIDOR DE TIROSINA-QUINASE. Albuquerque IM, Sartori DP, Vieira JB, Romero JF, Neto Vd, França AP, Nunes FM, Viana A, Rodrigues P, Gontei M, Junior AN, Rodrigues EX,UNIMED Fortaleza, Fortaleza, Brazil GASTO FARMACÉUTICO AMBULATORIO Y HOSPITALARIO EN PACIENTES CON CÁNCER DE MAMA EN LA COMUNIDAD DE VALENCIA. ANÁLISIS DE LO GRUPOS DE RIESGO CLÍNICO 2014-2015. Albanes Beltran JP1, Vivas Consuelo D2, Romero M3, Caballer V4, Alvis-Guzmán N5, De la Hoz Restrepo F1,1Universidad Nacional de Colombia, Bogotá, D.C., Colombia, 2Universidad Politécnica de Valencia, Valencia, Spain, 3Fundación Salutia, Bogotá D.C., Colombia, 4Universitat Politècnica de València, Valencia, Spain, 5Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia ECONOMIC EVALUATION OF THE CHANGE FROM AN OPPORTUNISTIC CERVICAL SCREENING PROGRAM TO AN ORGANIZED SCREENING IN CATALONIA, SPAIN Diaz M, Moriña D, Ibáñez R, Bruni L, de Sanjose S,Catalan Institute of Oncology-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain QUIMIOTERÁPICOS ORAIS NO TRATAMENTO DE SEGUNDA LINHA DO CARCINOMA DE CÉLULAS RENAIS: COMPARAÇÃO DE CUSTOS E PERFIL DE REAÇÕES ADVERSAS. Albuquerque IM, Vieira JB, Sartori DP, Romero JF, Neto Vd, Nunes FM, Rodrigues P, Viana A, Gontei M, Junior AN, Rodrigues EX,UNIMED Fortaleza, Fortaleza, Brazil XELOX VERSUS FOLFOX NO TRATAMENTO DO CÂNCER COLORRETAL: REVISÃO DE ESTUDOS FARMACOECONÔMICOS Boscato SC1, Godoy MR2, Heineck I1,1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Instituto de Avaliação de Tecnologia em Saúde - IATS, Porto Alegre, Brazil ANÁLISIS COMPARATIVO DE COSTOS ENTRE TRASTUZUMAB PARA ADMINISTRACIÓN SUBCUTÁNEA EN COMPARACIÓN CON LA FORMULACIÓN PARA ADMINISTRACIÓN INTRAVENOSA DESDE LA PERSPECTIVA DE LA SEGURIDAD SOCIAL COSTARRICENSE Castro Cordero JA, Marin Piva H, Ching Fung SM,Caja Costarricense de Seguro Social, San Jose, Costa Rica THE BURDEN OF UROTHELIAL CARCINOMA FOR THE BRAZILIAN PUBLIC HEALTH SYSTEM: A NATIONAL RETROSPECTIVE ANALYSIS FROM 2013 TO 2016 Chabrol Haas L, Peixoto RB, Coutinho MB, Serra FB,MSD Brasil, São Paulo, Brazil CUSTOS DIRETOS NO TRATAMENTO DE CÂNCER DE MAMA: OLHAR ESTRATÉGICO DE UMA OPERADORA DE PLANOS DE SAÚDE DO BRASIL. Albuquerque IM, Sartori DP, Vieira JB, Romero JF, Neto Vd, Nunes FM, França AP, Viana A, Rodrigues P, Gontei M, Junior AN, Rodrigues EX,UNIMED Fortaleza, Fortaleza, Brazil RESOURCE UTILIZATION AND TREATMENT OF PATIENT WITH HEPATOCELULLAR CARCINOMA – A MICROCOSTING ANALYSIS Turri JA1, Decimoni TC2, Ferreira LA3, Tomitao M4, Campolina AG4,1Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil, 2Sao Paulo Medical School, Sao Paulo, SK, Brazil, 3University of Sao Paulo, Sao Paulo, Brazil, 4Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil ECONOMIC ANALYSIS OF HEPATO CELLULAR CARCINOMA TREATMENT BY SEVERITY OF DISEASE Turri JA1, Campolina AG2, Decimoni TC3, Tomitao M2, Ferreira LA4,1Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil, 2Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil, 3Sao Paulo Medical School, Sao Paulo, SK, Brazil, 4University of Sao Paulo, Sao Paulo, Brazil OBINUTUZUMAB VS. IBRUTINIB IN THE TREATMENT OF TREATMENT-NAÏVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA —A COST-COMPARISON STUDY IN COLOMBIA
11
PCN26 F2
PCN27 F3
PCN28 F4
PCN29 F5
PCN31 F6
PCN32 F7
PCN33 F8
PCN34 F9
PCN35 F10
PCN36 F11
PCN37 F12
Vecino-Ortiz A1, Díaz-Sotelo OD2, Rodríguez M3, Diaz-Toro YR4, Moreno-Silva NA4,1Universidad de los Andes, Bogota, Colombia, 2Random Foundation, Bogota, Colombia, 3Fundación Santa Fe de Bogotá, Bogota, Colombia, 4Productos Roche S.A. Colombia, Bogotá, Colombia CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE Souza PV1, Zanini FE1, Biglia LV1, Kim HS2, Fahham L2,1Merck, São Paulo, Brazil, 2SENSE Company, São Paulo, Brazil COST PER RESPONSE ANALYSIS OF NIVOLUMAB VERSUS EVEROLIMUS IN THE TREATMENT OF PATIENTS PREVIOUSLY TREATED WITH ADVANCED RENAL CELL CARCINOMA – BRAZIL PRIVATE HEALTH CARE SYSTEM PERSPECTIVE Brust L1, Bernardino G2, Aratangy G2, Tanaka S2, Paladini L3, Borges L3, Clark OA4,1Centro Universitário Univates, Rio Grande do Sul, Brazil, 2Bristol-Myers Squibb, São Paulo, Brazil, 3Evidencias - Kantar Health, Campinas, Brazil, 4Evidencias - Kantar Health, Campinas, NJ, Brazil NUMBER NEEDED TO TREAT (NNT) AND COST OF PREVENTING AN EVENT (COPE) COMPARISON BETWEEN THE ASSOCIATION OF COBIMETINIB AND VEMURAFENIB AMONG OTHER TREATMENT OPTIONS FOR METASTATIC MELANOMA WITH BRAF V600 MUTATION Ho R, Rufino C, Simões J, Alves M,Roche Brazil, São Paulo, Brazil COST CONSEQUENCE ANALYSIS OF IMMUNE-ENHANCING NUTRITIONAL FORMULA IN PATIENTS WITH DIGESTIVE CANCER SURGERY Danel A1, Viana SD2, Dias A2, Lopez SN2, Tauil DA2, Meale MM2,1Nestle Health Science, Vevey, Switzerland, 2Nestle Health Science, Sao Paulo, Brazil INHIBITORS OF TIROSIN KINASA IN CHRONIC MIELOID LEUKEMIA: COST-EFFECTIVENESS ANALYSIS. Campos I1, Cordova P2, Fernandez P2, Lopez M2, Morales F2, Villa L2,1Universidad de Concepción, Concepción, Chile, 2Facultad de Farmacia, Universidad de Concepción, Concepción, Chile ACCUMULATED TREATMENT COST OF NEW THERAPIES IN MULTIPLE MYELOMA: COMPARING THE COMBINATION OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE WITH CARFILZOMIB AND DEXAMETHASONE FOR WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN BRAZIL Del Rey C, Asano E,Janssen, Sao Paulo, Brazil TREATMENT SEQUENCING FOR PATIENTS WITH MULTIPLE MYELOMA WITH AT LEAST ONE PRIOR LINE: COMPARING PROGRESSION-FREE SURVIVAL AND COSTS UNDER A PRIVATE PAYER PERSPECTIVE Asano E1, Maiolino A2, Martins E1,1Janssen, Sao Paulo, Brazil, 2UFRJ, Rio de Janeiro, Brazil COST AND EFFECTIVENESS OF THE USE OF SORAFENIB IN DIFFERENTIATED THYROID CANCER Carrasquilla-Sotomayor M1, Alvis-Zakzuk NJ2, Gomez de la Rosa F2, Alvis Zakzuk J1, Marrugo Figueroa RD3, Miranda Machado P1, Alvis Guzman N4, Herran Diazgranado SE3,1ALZAK Group, CARTAGENA, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3Bayer, Bogotá, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia ESTUDIO DE COSTO-EFECTIVIDAD E IMPACTO PRESUPUESTAL DE DENOSUMAB VS. ÁCIDO ZOLEDRÓNICO PARA EL MANEJO DE METÁSTASIS ÓSEAS EN PACIENTES CON CÁNCER DE PRÓSTATA EN COLOMBIA Pérez M1, Garcia Perlaza J1, Fletscher PM1, Vargas-Valencia J2,1AMGEN, Bogotá, Colombia, 2Econopharma Consulting, Mexico, Mexico COST PER MEDIAN OVERALL SURVIVAL ASSOCIATED WITH ABIRATERONE ACETATE AND ENZALUTAMIDE FOR TREATMENT OF PATIENTS WITH METASTATIC CASTRATIONRESISTANT PROSTATE CANCER IN COLOMBIA Aguirre A1, Guerrero E2,1Janssen Cilag SA, Bogota, Colombia, 2Janssen Colombia, Bogota, Colombia COSTO UTILIDAD DE LOS BLOQUEADORES HER2 CONTRA EL CÁNCER DE MAMA METASTÁSICO EN MUJERES PERUANAS Gutierrez-Aguado A1, Escobedo-Palza S2,1UNMSM, Lima, Peru, 2SPEAS, Lima, Peru
12
CANCER - Patient-Reported Outcomes & Patient Preference Studies PCN38 F13
PCN39 F14
ONCOLOGIC PAIN ATTITUDES, INTENSITY AND TREATMENT IN BRAZIL Holtz L1, Julian GS2, Cecilio L1, de Oliveira RW 2, Moreira Ed2,1Oncoguia, São Paulo, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil IMAGEM CORPORAL EM MULHERES SUBMETIDAS AO TRATAMENTO DO CÂNCER DE MAMA Guedes SR1, De Camargo Cancela M2, Dantas de Oliveira NP1, Martins Holanda A1, Albuquerque Reis M1, Patrocínio da Silva C1, Rocha e Silva BL1, Bezerra de Souza DL1,1Universidade Federal do Rio Grande do Norte, Natal, Brazil, 2Instituto Nacional de Câncer, Rio de Janeiro, Brazil
CANCER - Health Care Use & Policy Studies PCN40 F15 PCN41 F16
PCN42 F17
PCN43 F18
PCN44 G1
PCN45 G2
PCN46 G3
PCN47 G4
PINK OCTOBER IN THE SOCIAL MEDIA: ARE WE STILL (MIS)GUIDING THE PUBLIC? Bueno CC, Almeida PR, Clark LG,Evidencias - Kantar Health, Campinas, Brazil SUPPORTING INDIVIDUAL REFLECTION AND PATIENT-CLINICIAN SHARED DECISIONMAKING ON GEP-NET MANAGEMENT OPTIONS USING REFLECTIVE MULTI-CRITERIA DECISION ANALYSIS Wagner M1, Samaha D2, O'Neil B3, Khoury H3, Bennetts L3, Lavoie L3, Badgley D3, Gabriel S4, Berthon A4, Dinet J4, Dolan J5, Kulke MH6, Goetghebeur MM7,1Analytica LASER, Montreal, QC, Canada, 2LASER Analytica, London, UK, 3LASER Analytica, Montreal, QC, Canada, 4Ipsen Pharma SAS, Boulogne-Billancourt, France, 5University of Rochester, Rochester, NY, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA, 7Analytica LASER and School of Public Health, University of Montreal, Montreal, QC, Canada BREAST CANCER DIAGNOSIS PROCESS: AN INTEGRATIVE EVALUATION OF FIVE COMPONENTS. Pulido DC1, Alvis LF1, Gonzalez J2, Sanchez P1, Acuña L1, Bryón A3,1Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 2Oncólogos de Occidente, Pereira, Colombia, 3HEORT- Health Economics & Outcomes Research Team, Bogota, Colombia MULTIPLE MYELOMA PATIENTS’ PROFILE AND REGIMENS TRANSITIONS IN THE BRAZILIAN PRIVATE HEALTH SECTOR Lin HM1, Luptakova K1, Tanaka PY2, Andrade F2, Saad R3, Clark OA4,1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2Takeda Farmacêutica Brasil, São Paulo, Brazil, 3Evidencias - Kantar Health, Campinas, Brazil, 4Evidencias - Kantar Health, Campinas, NJ, Brazil USE OF BRENTUXIMAB VEDOTIN TO TREAT HODGKIN LYMPHOMA IN A PRIVATE SECTOR SETTING IN BRAZIL Andrade F1, Barreto T1, Zagadailov E2, Gautam A2, Clark OA3, Saad R4, Seal B2, Dalal M2, Baiocchi O5,1Takeda Farmacêutica Brasil, São Paulo, Brazil, 2Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 3Evidencias Kantar Health, Campinas, NJ, Brazil, 4Evidencias - Kantar Health, Campinas, Brazil, 5Universidade Federal de São Paulo, São Paulo, Brazil ANALYSIS OF METASTATIC BREAST CANCER POLICIES TO ADVANCE ACCESS TO TREATMENT IN LATIN AMERICA: RESEARCH METHODOLOGY AND APPROACHES USED TO SURVEY THE CURRENT POLICY ENVIRONMENT Dharssi S, Thrift Perry M,Pfizer, Inc, New York, NY, USA ANTINEOPLÁSICOS DE MAIOR IMPACTO FINANCEIRO NO INSTITUTO NACIONAL DE CANCER DO BRASIL Moraes EL1, Osorio-de-Castro CG2, Caetano R3,1National Cancer Institute, Rio de Janeiro, Brazil, 2Sergio Arouca National School of Public Health,Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 3Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil COMPRAS DE MEDICAMENTOS SEM LICITAÇÃO NO INSTITUTO NACIONAL DE CÂNCER DO BRASIL Moraes EL1, Osorio-de-Castro CG2, Caetano R3,1National Cancer Institute, Rio de Janeiro, Brazil, 2Sergio Arouca National School of Public Health,Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 3Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil
13
PCN48 G5
PCN49 G6
PCN50 G7
PCN51 G8
PCN52 G9
PCN53 G10
PCN54 G11
PCN55 G12
PCN56 G13
PCN57 G14
PCN58 G15
HIGH-COST ONCOLOGY DRUGS IN BRAZIL AND MEXICO: ACCESS DIFFERENCES BETWEEN THE PUBLIC AND PRIVATE SETTINGS Giao Antunes NT1, Ribeiro A1, Duval A2, Moore R3,1Decision Resources Group, Burlington, MA, USA, 2Decision Resources Group, London, UK, 3Decision Resources Group, Nashville, TN, USA REAL WORLD DATA ON MULTIPLE MYELOMA TREATMENT PATTERNS: FIRST AND SECOND-LINE TREATMENT IN THE BRAZILIAN PUBLIC HEALTH SYSTEM Lemmer T1, Martins RE1, Kashiura D1, Saad R2,1Evidências - Kantar Health, São Paulo, Brazil, 2Evidencias - Kantar Health, Campinas, Brazil ANÁLISE SITUACIONAL DO TRATAMENTO CIRÚRGICO DO CÂNCER COLORRETAL NO BRASIL Oliveira D1, Oliveira FM1, Junqueira Junior SM1, Luque A2,1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson&Johnson Medical Brazil, Sao Paulo, Brazil EVALUATION OF HEALTH CARE REFORM IMPACT ON CANCER PATIENTS` ACCESS TO MEDICINE: A PILOT-CENTER EXPERIENCE IN ISLAMIC REPUBLIC OF IRAN Mansoori M1, Zaboli P2, Saeedi M1, Janbabai G1, Nikfar S2, Rohani E3, Zartab S2,1Mazandaran University of Medical Sciences, Sari, Iran (Islamic Republic of), 2Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of), 3Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of) HEMATOPOIETIC CELL TRANSPLANTATION FACILITIES: GEOGRAPHIC ACCESS IN COLOMBIA. Uribe Parra D1, Soler LA1, Lopes G2, Acuña Merchan L1, Bermúdez NC1, Valencia O1, Gonzalez J3, Pulido DC1, Sanchez P1, Gutierrez A1,1Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 2Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, FL, 33136, Colombia, 3Oncólogos de Occidente, Pereira, Colombia EVALUATION OF HEALTH CARE REFORM IMPACT ON CANCER PATIENTS` TOTAL OUT OF POCKET: A PILOT-CENTER EXPERIENCE IN ISLAMIC REPUBLIC OF IRAN Sarkhanloo F1, Zaboli P2, Saeedi M1, Janbabai G1, Nikfar S3, Morteza-Semnani K4, Rohani E2, Ayati N2,1Mazandaran University of Medical Sciences, Sari, Iran (Islamic Republic of), 2Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of), 4Mazandaran University of Medical sciences, Sari, Iran (Islamic Republic of) QUIMIOTERAPIA DO CÂNCER NAS ÚLTIMAS SEMANAS DE VIDA: ESTUDO RETROSPECTIVO EM BENEFICIÁRIOS DE UM PLANO DE SAÚDE PRIVADO NO BRASIL Reis Neto JP1, Busch JM2, Stefani S1,1, Rio de Janeiro, Brazil, 2Souza Marques University, Rio de Janeiro, Brazil DISTRIBUIÇÃO DAS PRINCIPAIS NEOPLASIAS MALIGNAS SEGUNDO SEXO E ANO DE DIAGNÓSTICO, REGISTRO HOSPITALAR DE CÂNCER, INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO, 2008-2012 López RV1, Campolina AG2, Lopes EF1, Hoff PM3, Chammas R1,1Cancer Institute of the State of São Paulo, Sao Paulo, Brazil, 2Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil, 3Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil IMPACTO DO ENCAMINHAMENTO PRECOCE PARA CUIDADOS PALIATIVOS NA UTILIZAÇÃO DE ATENDIMENTOS DE EMERGÊNCIA POR PACIENTES COM CÂNCER AVANÇADO Rozman LM1, Campolina AG2, López RV3, Chiba T3, De Soárez PC4,1University of Sao Paulo, Sao Paulo, Brazil, 2Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil, 3Cancer Institute of the State of São Paulo, Sao Paulo, Brazil, 4University of Sao Paulo, Sao Paulo, Brazil INFLUÊNCIA DOS FATORES SOCIOECONÔMICOS NA INCIDÊNCIA DE CÂNCER DE MAMA: REVISÃO SISTEMÁTICA Massuda EM1, Tortajada Jd2, Oliveira TS2, Costa CK3,1Unicesumar/ICETI, MARINGA, Brazil, 2Unicesumar, MARINGA, Brazil, 3Universidade Estadual de Maringá, Maringá, Brazil BEVACIZUMAB FOR BREAST CANCER: SCIENTIFIC EVIDENCE VERSUS REAL WORLD DATA (RWD) IN BRAZIL Feijo L, Pegoretti Rosa B, Moraes Z, Goes L, Clark LG,Evidencias - Kantar Health, Campinas, Brazil
14
PCN59 G16 DENIED ONCOLOGY TREATMENT CLAIMS: HOW MUCH DO THEY COST AND HOW CAN WE PREVENT RESOURCE WASTE? Goes L, Castro AP, Pegoretti Rosa B, Clark LG,Evidencias - Kantar Health, Campinas, Brazil PCN60 H1 NEWEST TARGET THERAPY AND IMMUNOTHERAPY FOR THE TREATMENT OF ADVANCED MELANOMA: PATTERNS OF ADOPTION BY THE PRIVATE HEALTH CARE SECTOR IN BRAZIL Pegoretti Rosa B, Goes L, Moraes Z, Feijo L, Clark LG,Evidencias - Kantar Health, Campinas, Brazil PCN61 H2 REAL-WORLD TREATMENT PATTERNS IN STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ARGENTINA Novick D1, Hong J2, Sheffield KM3, Mills BJ4, Gallino J5,1Eli Lilly and Company, Windlesham, Surrey, UK, 2Gachon University, Seongnam, Korea, Republic of (South), 3Eli Lilly and Company, Indianapolis, IN, USA, 4Elilly and Company, Indianapolis, IN, USA, 5Institute of Medical Specialties SA, Pilar, Argentina PCN62 H3 REAL WORLD TREATMENT PATTERNS IN METASTATIC AND/OR UNRESECTABLE GASTRIC CANCER PATIENTS. PRELIMINARY RESULTS FROM COLOMBIA Novick D1, Leonardi Reyes F2, Lee Kay Pen ED3, Siddi S4, Haro JM5, Velasquez JC6,1Eli Lilly and Company, Windlesham, Surrey, UK, 2Eli Lilly, Bogota, Colombia, 3LACAM Eli Lilly and Company, LIMA, Peru, 4Parc SanitariSant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Spain, 5Parc Sanitari Sant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Spain, 6Instituto Nacional de Cancerología E.S.E, Bogotá, Colombia PCN63 H4 REAL WORLD TREATMENT PATTERNS IN METASTATIC AND/OR UNRESECTABLE GASTRIC CANCER IN PATIENTS FROM ARGENTINA Novick D1, Mendenz G2, Carballido M3, Rizzo M3, O'Connor JM4, Castillo J5, Lee Kay Pen ED6, Siddi S7, Rodante D8, Haro JM9,1Eli Lilly and Company, Windlesham, Surrey, UK, 2Fundación Favaloro para la Docencia e Investigación médica, Buenos Aires, Argentina, 3Hospital de Gastroenterología “Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina, 4Instituto Alexander Fleming, Buenos Aires, Argentina, 5Hospital Alemán Asociación Civil, Buenos Aires, Argentina, 6LACAM Eli Lilly and Company, LIMA, Peru, 7Parc SanitariSant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Spain, 8Hospital Neuropsiquiátrico "Dr. Braulio A. Moyano", Buenos Aires, Argentina, 9Parc Sanitari Sant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Spain GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies PGI1 H5
PGI2 H6
PGI3 H7
PGI4 H8
PGI5 H9
SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES OF INTERFERON-FREE TREATMENTS FOR CHRONIC HEPATITIS C Ferreira VL, Leonart L, Tonin FS, Pontarolo R,Universidade Federal do Paraná, Curitiba, Brazil BOCEPREVIR AND TELAPREVIR EFFECTIVENESS AND SAFETY IN A BRAZILIAN COHORT OF CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS: A MULTICENTRIC LONGITUDINAL STUDY Borba HH1, Wiens A1, Steimbach LM1, Tonin FS1, Pedroso ML2, Minowa E3, Piedade A4, Clark O4, Fernandez-Llimos F5, Pontarolo R1,1Universidade Federal do Paraná, Curitiba, Brazil, 2Gastroenterology Service, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil, 3Universidade de São Paulo, São Paulo, Brazil, 4Evidências-A Kantar Health Company, Rio de Janeiro, Brazil, 5University of Lisboa, Lisboa, Portugal PREVALENCE AND ANTIMICROBIAL SENSITIVITY OF SALMONELLA FROM FECAL AND MILK SAMPLES OF LACTATING COWS, DEBRE-ZEIT, ETHIOPIA Yizengaw HA,Dilla University, Dilla, Ethiopia GENOTYPE AND LIVER FIBROSIS DISTRIBUTION AMONG HEPATITIS C PATIENTS IN A SINGLE CENTER IN THE SOUTH OF BRASIL: A CROSS-SECTIONAL STUDY Borba HH1, Wiens A1, Ivantes CA2, Santos JC2, Tawil FB2, Pontarolo R1,1Universidade Federal do Paraná, Curitiba, Brazil, 2Centro de Orientação e Aconselhamento - COA, Curitiba, Brazil WAITING LIST MORTALITY IMPACT IN HCV CIRRHOTIC PATIENTS Silva G1, Andrade VG1, Paixão VN1, Pardini MI1, Grotto R1, Bráz AM1, Golim M1, Yamashiro FS1, Oliveira CV1, Lastoria L1, Moreira A1, Fernandes AS2,1UNESP, Botucatu, Brazil, 2MSD, São Paulo, Brazil
GASTROINTESTINAL DISORDERS - Cost Studies PGI6 H10 HOW DOES HIGH MELD SCORE INCREASES TOTAL EXPENDITURE ON HEALTH SYSTEM? A MICRO-COSTING PROSPECTIVE COHORT STUDY.
15
Turri JA1, Ferreira LA2, Decimoni TC3, Campolina AG4,1Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil, 2University of Sao Paulo, Sao Paulo, Brazil, 3Sao Paulo Medical School, Sao Paulo, SK, Brazil, 4Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil PGI7 H11 COSTO DE LA ATENCIÓN DE LA ENFERMEDAD DE CROHN EN UN CENTRO ASISTENCIAL DE BOGOTÁ, COLOMBIA Molano B1, Bryón A2, Jaimes D3,1fundacion santafe de bogota, Bogota, Colombia, 2HEORT - Health Economics & Outcomes Research Team, Bogota, Colombia, 3HEORT, Bogota, Colombia PGI8 H12 CUSTO EFETIVIDADE DO USO DOS INIBIDORES DE PROTEASE NO TRATAMENTO DA HEPATITE C CRÔNICA: COMPARAÇÃO ENTRE O USO UNIVERSAL E O USO RESTRITO NA FIBROSE AVANÇADA. Rodrigues MP1, Mosegui GB2, Vianna CM3, Oliveira FS1, da Cunha GN3, Jardim FN3, Valle PM3,1UERJ, Rio de Janeiro,, Rio de Janeiro, Brazil, 2Universidade Federal Fluminense, Niterói, Brazil, 3Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil PGI9 H13 EFFECTIVENESS AND COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR AND BOCEPREVIR FOR CHRONIC HEPATITIS C: A DECISION ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM Borba HH1, Rochau U2, Wiens A1, Sroczynski G3, Siebert U4, Pontarolo R1,1Universidade Federal do Paraná, Curitiba, Brazil, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making & HTA, Dept. of Public Health, Health Services Research and HTA, Hall i.T., Austria, 3UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, 4Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies PGI10 H14 A CONCEPTUAL MODEL FOR PEDIATRIC GASTROESOPHAGEAL REFLUX Smith AB1, Hodgkinson V1, Okhuoya P1, Tatlock S2, Spencer H3, Arbuckle R3,1RB, Hull, UK, 2Adelphi Values Ltd, Bollington, UK, 3Adelphi Values Ltd, Bollington, Cheshire, UK MENTAL HEALTH - Clinical Outcomes Studies PMH1 H15 METANÁLISE DE SEGURANÇA DO TRATAMENTO MEDICAMENTOSO DE PACIENTES COM TRANSTORNO DO DÉFICIT DA ATENÇÃO COM HIPERATIVIDADE E ANSIEDADE Borges dos Reis C1, Oliveira DC2, Fernandez-Llimos F3, Oliota AF1, Pontarolo R4, Sanches AC1,1Universidade Estadual do Oeste do Paraná, Cascavel, Brazil, 2Universidade Estadual de Maringá, Maringá, Brazil, 3Universidade de Lisboa, Lisboa, Portugal, 4Universidade Federal do Paraná, Curitiba, Brazil PMH2 H16 AVALIAÇÃO DA REDUÇÃO DE REHOSPITALIZAÇÃO DOS PACIENTES COM ESQUIZOFRENIA, TRATADOS COM PALMITATO DE PALIPERIDONA Klingelfus BL1, Ramires Y2, Sousa FM1, Oliveira K1, Yamasaka FM1,1Unimed Curitiba, Curitiba, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil PMH3 I1 META-ANÁLISE DE EFICÁCIA DA ATOMOXETINA EM ADULTOS COM TRANSTORNO DE DÉFICIT DA ATENÇÃO COM HIPERATIVIDADE Oliveira DC1, Sousa PG2, Borges dos Reis C2, Virtuoso S2, Tonin FS3, Sanches AC2,1Universidade Estadual de Maringá, Maringá, Brazil, 2Universidade Estadual do Oeste do Paraná, Cascavel, Brazil, 3Universidade Federal do Paraná, Curitiba, Brazil PMH4 I2 ALCOHOL USE AND RELATED HEALTH PROBLEMS AMONG ETHIOPIAN ADULTS IN GONDAR: A CROSS SECTIONAL STUDY Bhagavathula AS1, Tegegn HG2, Achaw A2,1University of Gondar- College of Medicine and Health Sciences, Gondar, Ethiopia, 2University of Gondar, Gondar, Ethiopia PMH5 I3 BURNOUT SYNDROME AMONG HEALTHCARE PROFESSIONALS WORKING IN GONDAR UNIVERSITY HOSPITAL, NORTHWEST ETHIOPIA: A CROSS-SECTIONAL STUDY Bhagavathula AS1, Abegaz TM2, Belachew SA1, Gebreyohannes EA3, Gebresillasie Bm3,1University of Gondar- College of Medicine and Health Sciences, Gondar, Ethiopia, 2University of GondarCollege of Medicine and Health Sciences, Gondar, Ethiopia, 3University of Gondar, Gondar, Ethiopia
16
MENTAL HEALTH - Cost Studies PMH6 I4
PMH7 I5
PMH8 I6
PMH9 I7
PMH10 I8
PMH11 I9
ANÁLISE DE CUSTO-COMPARAÇÃO ENTRE OS PROGRAMAS PARA PESSOAS COM DEFICIÊNCIA INTELECTUAL E DO DESENVOLVIMENTO COGNITIVO: SUPORTE INDIVIDUALIZADO E INSTITUIÇÕES DE SAÚDE MENTAL. Koury DaLee C,University of Colorado, Denver, CO, USA RESOURCE ALLOCATION FOR TREATING ALCOHOL AND DRUG MISUSE IN PSYCHOSOCIAL CARE CENTER IN BRAZIL: IS CURRENT NATIONAL FUNDING ENOUGH FOR COVERING ITS TOTAL COSTS? Becker P, Razzouk D,Universidade Federal de São Paulo, São Paulo, Brazil ESTIMATION OF THE COST OF RELAPSE IN SCHIZOPHRENIA: A COMPARISON BETWEEN COLOMBIA, PANAMA AND MEXICO Guirant Corpi L1, Aguirre A2, Suppini V3, Aguirre A1, Guerrero E2, Arias J4,1Janssen Mexico, Mexico City, Mexico, 2Janssen Cilag SA, Bogota, Colombia, 3Janssen Central America and the Caribbean, Panama, Panama, 4Janssen-Cilag Farmacêutica Ltda, São Paulo, Brazil THE IMPACT OF LONG ACTING INJECTABLE ANTIPSYCHOTICS ON THE HEALTH AND ECONOMIC OUTCOMES OF SCHIZOPHRENIA PATIENTS IN BRAZIL Ferreira KA1, Arias J2, Keenan A3, Zheng Y3,1Janssen-Cilag Farmacêutica Ltda, São Paulo, Brazil, 2Janssen-Cilag Latin America, Panama city, Panama, 3Janssen R&D US, Raritan, NJ, USA AVALIAÇÃO DOS CUSTOS POR TIPO DE INTERNAÇÃO EM UMA OPERADORA DE PLANOS DE SAÚDE: UMA ANÁLISE DE DADOS DO MUNDO REAL Viana A, Viana J, Albuquerque IM, Matias C, Gontei M, Silva MO,UNIMED Fortaleza, Fortaleza, Brazil ECONOMIC EVALUATION OF AYAHUASCA TREATMENT FOR SUBSTANCE USE DISORDER (SUD) PATIENTS IN A PERUVIAN CENTRE. Triulzi I1, Politi M2, Mendive F2, Palla I1, Turchetti G1,1Scuola Superiore Sant'Anna, Pisa, Italy, 2Takiwasi Center, Tarapoto, Peru
MENTAL HEALTH - Health Care Use & Policy Studies PMH13 I10
COMMUNITY PHARMACISTS’ INTEREST IN AND ATTITUDE TO PHARMACY PRACTICE RESEARCH IN ETHIOPIA: A CROSS-SECTIONAL STUDY Bhagavathula AS1, Gebreyohannes EA2, Gebresillasie Bm2, Erku DA2,1University of GondarCollege of Medicine and Health Sciences, Gondar, Ethiopia, 2University of Gondar, Gondar, Ethiopia
NEUROLOGICAL DISORDERS - Clinical Outcomes Studies PND1 I11 OSTEOPATHIC MANIPULATIVE THERAPY IN PATIENTS WITH HEADACHE: SYSTEMATIC LITERATURE REVIEW Vasconcellos JF1, Vasconcellos BC2, Fernandes RA1,1Sense Company, Rio de Janeiro, Brazil, 2CERTO Reabilitação, Rio de Janeiro, Brazil PND2 I12 EFFECTIVENESS OF LACOSAMIDE FOR THE TREATMENT OF NON-CONTROLLED FOCAL EPILEPSY Morita ME1, Psaltikidis EM1, Soares E1, Cendes F1, Yasuda CL1, Evangelista-Poderoso R2, Resende MR3, Betting LE4,1Clinical Hospital of State University of Campinas, Campinas, Brazil, 2Faculty of Medical Sciences of State University of Campinas, Campinas, Brazil, 3Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil, 4Botucatu Medical School of the Universudade Estadual Paulista – UNESP, Botucatu, Brazil PND3 I13 EVALUACIÓN DE EFECTIVIDAD Y SEGURIDAD DE LA TERAPIA FARMACOLÓGICA PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON INICIAL Y AVANZADA EN COLOMBIA. Contreras J, Castro P, Sierra J, Orozco L,Universidad de Antioquia, Medellín, Colombia NEUROLOGICAL DISORDERS - Cost Studies PND4 I14 ANÁLISE DE CUSTO EFETIVIDADE DA TOXINA ONABOTULÍNICA A NO TRATAMENTO PREVENTIVO DA MIGRÂNEA CRÔNICA Cadecaro P1, Pepe C2, Asano E2, Romariz G1,1Allergan, Sao Paulo, Brazil, 2Sense Company, São Paulo, Brazil
17
PND5 I15 ANÁLISIS DE COSTO-EFECTIVIDAD DE LA MONOTERAPIA CON RASAGILINA COMPARADA CON PRAMIPEXOL PARA EL MANEJO DE LOS SÍNTOMAS MOTORES EN PACIENTES CON ENFERMEDAD DE PARKINSON INICIAL EN COLOMBIA. Castro P, Orozco L, Contreras J, Sierra J, Sanmartín D,Universidad de Antioquia, Medellín, Colombia
NEUROLOGICAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies PND6 I16 RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS ON DIMETHYL FUMARATE REPORTED LESS PHYSICAL AND PSYCHOLOGICAL DISEASE IMPACT IN THE REAL WORLD COMPARED WITH PATIENTS ON PLATFORM THERAPIES Huang M1, Pike J2, Huang W3, Jones E4,1Biogen, Cambridge, MA, USA, 2Adelphi Real World, Cheshire, UK, 3UCSF, San Francisco, CA, USA, 4Adelphi Real World, Manchester, UK NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies PND7 J1
PND8 J2
PND9 J3
PIPELINE ASSESSMENT OF ΒETA-SECRETASE INHIBITORS FOR ALZHEIMER’S DISEASE: HOPES OR GLOOM FOR A TRILLION DOLLAR MARKET Gautam R,Optum Global Solutions, Noida, India ANTICONVULSANT DRUGS USE EVALUATION SURVEY AMONG AMBULATORY EPILEPTIC PATIENTS IN A TERTIARY TEACHING HOSPITAL IN SOUTHEAST NIGERIA Ogbonna BO, Ume IO,NNAMDI AZIKIWE UNIVERSITY, AWKA, Nigeria OBSTRUCTIVE SLEEP APNEA TREATMENT GUIDELINES - IMPLEMENTATION STATUS IN OECD-COUNTRIES Braun M1, Heiser C2,1Inspire Medical Systems, Inc., Maple Grove, MN, USA, 2Technical University Munich, Munich, Germany
RESPIRATORY-RELATED DISORDERS - Clinical Outcomes Studies PRS1 J4
PRS2 J5
PRS3 J6
EFFECT OF HESPERIDIN IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN RATS: CRITICAL ROLE OF NRF-2, TNF-Α, AND IL-1Β Kandhare AD, Mukherjee A, Bodhankar SL,Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India DRUG-SAFETY PROGRAM IMPACT IN HOSPITALIZATION PERSISTENT SEVERE ASTHMA PATIENTS. Estrada JI1, Restrepo AM1, Giraldo PA1, Abad JM2, Serna JA1, Segura AM3,1+helPharma IPS, Medellin, Colombia, 2SURA EPS, Medellin, Colombia, 3CES University, Medellin, Colombia DRUG-SAFETY PROGRAM IMPACT IN THE EMERGENCY FREQUENCY AT PATIENTS WITH PERSISTENT SEVERE ASTHMA. Estrada JI1, Restrepo AM1, Giraldo PA1, Serna JA1, Abad JM2, Segura AM3,1+helPharma IPS, Medellin, Colombia, 2SURA EPS, Medellin, Colombia, 3CES University, Medellin, Colombia
RESPIRATORY-RELATED DISORDERS - Cost Studies PRS5 J7
ESTIMATING THE FINANCIAL IMPACT OF INTRODUCING GLYCOPYRRONIUM BROMIDE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE PERSPECTIVE OF PUBLIC PAYER OF SÃO PAULO (SP) – BRAZIL. Suzuki C, Lopes N,Novartis Biociências SA, Sao Paulo, Brazil PRS6 J8 BUDGET IMPACT ANALYSIS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN COLOMBIA Patino A, Karpf E,Novartis Colombia, Bogota, Colombia PRS7 J9 QUALITY OF LIFE AND ECONOMIC BURDEN AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN JAPAN Kubota K1, Igarashi A2, Saito Y3, Oyamada M4, Miyata T4,1Yokohama City University, Yokohama, Japan, 2University of Tokyo, Tokyo, Japan, 3Kyoto University School of Public Health, Kyoto, Japan, 4Health and Global Policy Institute, Tokyo, Japan PRS8 J10 ANÁLISE DE CUSTO-EFETIVIDADE DO TRATAMENTO DIRETAMENTE OBSERVADO DA TUBERCULOSE
18
Gomes MP1, Nunes AA2, Sarti FM3, Ruffino Netto A1,1Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil, 2University of São Paulo, Ribeirão Preto, Brazil, 3University od São Paulo, São Paulo, Brazil PRS9 J11 ANÁLISIS DE COSTO EFECTIVIDAD DEL USO DE BUDESONIDA/FORMOTEROL FRENTE A SALMETEROL/FLUTICASONA, EN PACIENTES CON ASMA MODERADA Y SEVERA EN COLOMBIA Romero Prada ME, Roa Cardenas NC, Huerfano LM,Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia PRS10 J12 COST-UTILITY OF THE FIXED COMBINATION OF INDACATEROL/GLYCOPYRONIUM VS. SALMETEROL/FLUTICASONE AND TIOTROPIUM IN THE MANAGEMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN COLOMBIA Patino A1, Londoño D2, Karpf E1,1Novartis Colombia, Bogota, Colombia, 2Fundacion Santa Fe de Bogota, Bogota, Colombia RESPIRATORY-RELATED DISORDERS - Patient-Reported Outcomes & Patient Preference Studies PRS11 J13 DRUG-SAFETY PROGRAM IMPACT AT HEALTH RELATED QUALITY OF LIFE AT PATIENTS DIAGNOSED WITH PERSISTENT SEVERE ASTHMA. Estrada JI1, Restrepo AM1, Giraldo PA1, Abad JM2, Serna JA1, Segura AM3,1+helPharma IPS, Medellin, Colombia, 2SURA EPS, Medellin, Colombia, 3CES University, Medellin, Colombia PRS12 J14 DRUG-SAFETY PROGRAM IMPACT AT HEALTH CARE PERCEPTION AT PATIENTS DIAGNOSED WITH PERSISTENT SEVERE ASTHMA. Estrada JI1, Restrepo AM1, Giraldo PA1, Serna JA1, Abad JM2, Segura AM3,1+helPharma IPS, Medellin, Colombia, 2SURA EPS, Medellin, Colombia, 3CES University, Medellin, Colombia PRS13 J15 AVALIAÇÃO DA QUALIDADE DE VIDA EM CRIANÇAS E ADOLESCENTES COM ASMA Almeida A1, Figueiredo C2, Rodrigues C3,1Universidade da Beira Interior, COVILHA, Portugal, 2Universidade da Beira Interior, Covilhã, Portugal, 3Centro Hospitalar Cova da Beira, Covilhã3, Portugal SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies PSY2 J16
PSY3 K1
PSY4 K2
PSY5 K3
PSY6 K4
SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF AMFEPRAMONE AND MAZINDOL AS A MONOTHERAPY FOR THE TREATMENT OF OBESE OR OVERWEIGHT PATIENTS Lucchetta R1, Riveros B1, Pontarolo R2, Radominski R1, Otuki M1, Fernandez-Llimos F3, Correr C1,1Federal University of Parana, Curitiba, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Universidade de Lisboa, Lisboa, Portugal MEDICAL TREATMENTS FOR ACROMEGALY: SYSTEMATIC REVIEW AND NETWORK METAANALYSIS Leonart LP, Ferreira VL, Tonin FS, Pontarolo R,Universidade Federal do Paraná, Curitiba, Brazil ASSOCIATION BETWEEN SECOND-LINE THERAPY (2LT) REGIMEN TYPE, DURATION OF THERAPY (DOT), AND TIME TO NEXT TREATMENT (TTNT) IN A UNITED STATES (US) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) COHORT: AN ELECTRONIC MEDICAL RECORDS (EMR)-BASED STUDY Romanus D1, Raju A2, Yong C1, Farrelly E2, Luptakova K1, Labotka R1, Noga SJ1, Blazer M2, Hari P3,1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA, 3Medical College of Wisconsin, Division of Hematology Oncology, Milwaukee, WI, USA USE OF THALIDOMIDE IN ERYTHEMATOSUS LUPUS TREATMENT Teixeira DR1, Galdino-Pitta MR1, Nunes TR2, Viana DC3, Araujo BC2, Zanghelini F4, Pereira MC2, Rego MJ4, Oliveira MD5, Pitta Id4, Pitta MG2, Andrade CA2,1Federal University of Pernambuco, Recife, Brazil, 2Universidade Federal de Pernambuco, Recife, Brazil, 3Avenida Professor Moraes Rego, Recife, Brazil, 4UFPE, Recife, Brazil, 5University Federal de Pernambuco, Recife, Brazil TREATMENT PATTERNS AND IMPACT OF NOT ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS IN LATIN AMERICA Papadimitropoulos M1, Romiti R2, Garcia EG3, Lobosco S4, Leonardi Reyes F5, Wang X6, Haynes G7,1Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 2Hospital das Clínicas University of São Paulo (USP), São Paulo,
19
PSY7 K5
PSY8 K6
PSY9 K7
PSY10 K8
Brazil, 3Elil Lilly and Co, Mexico City, Mexico, 4Adelphi Real World, Macclesfield, UK, 5Eli Lilly, Bogota, Colombia, 6University of Toronto, Toronto, ON, Canada, 7Eli Lilly and Company, Indianapolis, IN, USA CHARACTERISTICS OF LATIN AMERICAN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADVANCED THERAPY Brnabic A1, Xavier R2, Goncalves L3, Lucas J4, Hernandez P5, Gaich CL6, Papadimitropoulos M7,1Eli Lilly and Company, Sydney, Australia, 2Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Eli Lilly and Company, São Paulo, Brazil, 4Adelphi Real World, Bollington, UK, 5Compañía Farmacéutica Eli Lilly de Centroamérica, S.A, Este San José, Costa Rica, 6Eli Lilly and Company, Indianapolis, IN, USA, 7Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada CHARACTERISTICS OF PSORIASIS PATIENTS IN LATIN AMERICA Burge R1, Galimberti R2, Goncalves L3, Lucas J4, Wang X5, Botello BS6, Brnabic A7,1Eli Lilly and Company, Indianapolis, USA; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH, USA, 2Universidad de Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Eli Lilly and Company, São Paulo, Brazil, 4Adelphi Real World, Bollington, UK, 5University of Toronto, Toronto, ON, Canada, 6Eli Lilly and Company, Mexico City, Mexico, 7Eli Lilly and Company, Sydney, Australia BURDEN OF DISEASE FOR PSORIASIS IN ARGENTINA, BRAZIL, COLOMBIA AND MEXICO Papadimitropoulos M1, Romiti R2, Guerra MA3, Vorstenbosch E4, Brnabic A5, Haynes G6, Goncalves L7, Leonardi Reyes F8, Garcia EG9, Burge R10,1Eli Lilly and Company, Canada; University of Toronto, Toronto, ON, Canada, 2Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil, 3Monterrey, Nuevo Leon, Mexico, 4Parc Sanitari Sant Joan de Deu, Barcelona, Spain, 5Eli Lilly and Company, Sydney, Australia, 6Eli Lilly and Company, Indianapolis, IN, USA, 7Eli Lilly and Company, São Paulo, Brazil, 8Eli Lilly, Bogota, Colombia, 9Elil Lilly and Co, Mexico City, Mexico, 10Eli Lilly and Company, Indianapolis, USA; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH, USA TREATMENT PATTERNS AND SATISFACTION FOR RHEUMATOID ARTHRITIS PATIENTS IN LATIN AMERICA UNDERGOING ADVANCED THERAPY Papadimitropoulos M1, Mysler E2, Garcia EG3, Lobosco S4, Botello BS5, Leonardi Reyes F6, Haynes G7,1Eli Lilly and Company, Canada; University of Toronto, Toronto, ON, Canada, 2Reumatología, Organización Médica de Investigación, Buenos Aires, Argentina, 3Elil Lilly and Co, Mexico City, Mexico, 4Adelphi Real World, Macclesfield, UK, 5Eli Lilly and Company, Mexico City, Mexico, 6Eli Lilly, Bogota, Colombia, 7Eli Lilly and Company, Indianapolis, IN, USA
SYSTEMIC DISORDERS/CONDITIONS - Cost Studies PSY11 K9
PSY12 K10
PSY13 K11
PSY14 K12
PSY15 K13
BUDGET IMPACT OF INTRODUCING SECUKINUMAB IN THE TREATMENT OF MODERATE-TOSEVERE PLAQUE PSORIASIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL Suzuki C, Lopes N,Novartis Biociências SA, Sao Paulo, Brazil BUDGET IMPACT OF THE INCLUSION OF OXYCODONE IN THE BRAZILIAN PUBLIC HEALTHCARE SETTING FOR THE TREATMENT OF CANCER PAIN Souza DA1, Aguiar EC1, Miguel AK2, Rosim RP2, Ballalai Ferraz AF2,1Mundipharma, São Paulo, Brazil, 2QuintilesIMS, São Paulo, Brazil AN OBSERVATIONAL RETROSPECTIVE COHORT DATABASE STUDY TO ESTIMATE COSTS REGARDING IMMUNOGLOBULIN USE FOR ITP TREATMENT IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM Figueiredo AC1, dos Santos RF2, Manfrin DF2, Lemos M3,1Amgen, sao paulo, Brazil, 2Amgen, São Paulo, Brazil, 3Amgen, São Paulo, Brazil REAL-WORLD HEALTH CARE EXPENDITURE IN HEMOPHILIA A PATIENTS USING STANDARD AND EXTENDED HALF-LIFE RECOMBINANT FACTOR VIII PRODUCTS Chhabra A1, Tortella BJ2, Alvir J1, Estevez C2, Spurden D3, Hodge J1, McDonald M1, Pleil A4,1Pfizer Inc, New York, NY, USA, 2Pfizer Inc, Collegeville, PA, USA, 3Pfizer Limited, Surrey, UK, 4Pfizer Inc, San Diego, CA, USA BURDEN OF DISEASE FOR RHEUMATOID ARTHRITIS IN ARGENTINA, BRAZIL, COLOMBIA, MEXICO AND VENEZUELA Papadimitropoulos M1, Castelar G2, Brnabic A3, Vorstenbosch EC4, Garcia EG5, Botello BS5, Hernandez P6, Goncalves L7, Gaich CL8,1Eli Lilly and Company, Canada; University of Toronto, Toronto, ON, Canada, 2Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 3Eli Lilly and
20
PSY16 K14
PSY17 K15
PSY18 K16
PSY19 K17
PSY20 K18
PSY21 L1
PSY22 L2
PSY23 L3
PSY24 L4
PSY25 L5
PSY26 L6
PSY27 L7
PSY28 L8
Company, Sydney, Australia, 4Parc Sanitari Sant Joan de Deu, Barcelona, Spain, 5Eli Lilly and Company, Mexico City, Mexico, 6Compañía Farmacéutica Eli Lilly de Centroamérica, S.A, Este San José, Costa Rica, 7Eli Lilly and Company, São Paulo, Brazil, 8Eli Lilly and Company, Indianapolis, IN, USA IDIOPATHIC PULMONARY FIBROSIS: WHERE THE FUNCTIONAL HEALTH DETERIORATION AND THE HIGH ECONOMIC IMPACT ARE INSEPARABLE. CHALLENGES IN A LATIN AMERICAN COUNTRY Moreno-Silva NA, Diaz-Toro YR,Productos Roche S.A. Colombia, Bogotá, Colombia DIRECT COSTS OF HEALTH CARE OF CYSTIC FIBROSIS, THE CASE OF A HEALTH INSURER IN COLOMBIA. Hoyos-Beltrán FJ1, Guarin NE1, Moreno JA1, Muñoz-Galindo IM1, Arevalo HO1, Diaz JA2,1Salud Total EPS, Bogotá D.C., Colombia, 2Universidad Nacional de Colombia, Bogotá D.C., Colombia ANTIBIOTICS TREATMENT PATTERNS AS A COSTS AND RESOURCE UTILIZATION PREDICTOR AMONG PATIENTS SUBMITTED TO BARIATRIC SURGERY: ANALYSIS OF A LARGE HEALTH INSURANCE CLAIMS DATABASE Luque A, Junqueira Junior SM, Oliveira D, Oliveira FM,Johnson & Johnson Medical Brazil, São Paulo, Brazil PUBLIC HEALTH EXPENDITURE IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA IN MEXICAN INSTITUTIONS Herrera M1, Salazar A2, Aguirre A3, Fritz K3,1Janssen, Mexico City, Mexico, 2Janssen Mexico, Mexico City, IL, USA, 3Janssen Mexico, Mexico City, Mexico CUSTO DE TRATAMENTO BIOLÓGICO EM PACIENTES COM DOENÇAS REUMÁTICAS EM UMA OPERADORA DE SAÚDE DE FORTALEZA/CE Neto Vd, Barroso FD, Albuquerque IM, Vieira JB, Sartori DP, Romero JF, Viana A, Junior AN, Rodrigues EX,UNIMED Fortaleza, Fortaleza, Brazil TREATMENT COST COMPARISON OF PIRFENIDONE VERSUS NINTEDANIB ON THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS Ho R, Rufino C, Lisondo C, Alves M,Roche Brazil, São Paulo, Brazil ECONOMIC EVALUATION OF ROMIPLOSTIM VS ELTROMBOPAG IN THE TREATMENT OF ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA IN MEXICO Naranjo M1, Alva ME1, Carlos F2,1Amgen, Mexico City, Mexico, 2R A C Salud Consultores S.A. de C.V, Mexico City, Mexico ESTUDOS ECONÔMICOS DE BELIMUMABE NO TRATAMENTO DO LÚPUS ERITEMATOSO SISTÊMICO - UMA REVISÃO SISTEMÁTICA Salgado JB1, Santos FM1, Lamarão FR2, Saturnino LT1,1GlaxoSmithkline, Rio de Janeiro, Brazil, 2GlaxoSmithKline, Rio de Janeiro, Brazil COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE VERSUS NINTEDANIB ON THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS Ho R, Rufino C, Lisondo C, Alves M,Roche Brazil, São Paulo, Brazil COSTO-EFECTIVIDAD DE LA CIRUGÍA BARIÁTRICA EN COLOMBIA Gil-Rojas Y1, Lasalvia P1, Hernández F2, Garzón A3, Andrade PC4, Rosselli D3,1Pontificia Universidad Javeriana, Bogota, Colombia, 2NeuroEconomix, Bogota, Colombia, 3Pontificia Universidad Javeriana, Bogotá, Colombia, 4Johnson & Johnson Medical, Bogotá, Colombia THE COST EFFECTIVENESS OF OXYCODONE IN PATIENTS WHO DO NOT RESPOND TO MORPHINE FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE Souza DA1, Aguiar EC1, Miguel AK2, Rosim RP2, Ballalai Ferraz AF2,1Mundipharma, São Paulo, Brazil, 2QuintilesIMS, São Paulo, Brazil PLAQUE PSORIASIS IN BULGARIA: COMPARATIVE ANALYSIS AND HEALTH TECHNOLOGY ASSESSMENT Djambazov S, Vekov T,Medical University Pleven, Pleven, Bulgaria COST-MINIMIZATION OF ADALIMUMAB AND INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS REFRACTORY TO CONVENTIONAL THERAPY
21
PSY29 L9
PSY30 L10
PSY31 L11
Jones K1, Rivera Hurtado R2, Ruet E2, Chaves L3, Izquierdo C3, Monroy Cruz B1, Gay Molina JG4, Gonzalez Godinez I4,1ti Salud, Mexico City, Mexico, 2Abbvie, Mexico City, Mexico, 3AbbVie Inc., North Chicago, IL, USA, 4T.I. Salud, Mexico D.F., Mexico ESTUDIO DE COSTO EFECTIVIDAD DEL FACTOR DE COAGULACIÓN RECOMBINANTE VIII UNIDO A PROTEINA FC PARA EL TRATAMIENTO DE LA HEMOFILIA A EN CHILE Vargas C1, Balmaceda C1, Rodriguez F2, Rojas R1, Espinoza MA3,1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad San Sebastián, Santiago, Chile, 3e Investigador Visitante Honorario, Centro para la Economía de Salud, Universidad de York, York, UK COST-UTILITY ANALYSIS OF TAPENTADOL PROLONGED RELEASE VERSUS OXYCODONE CONTROLLED RELEASE IN THE FIRST-LINE TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN UNDER THE PERSPECTIVE OF THE COLOMBIAN SUBSIDIZED PUBLIC HEALTHCARE SYSTEM Lemmer T1, Piedade A1, Engel T1, Sales L1, Martinez C2, Marcondes L2, Fernandez D3, Rojas S3, Mojica C3, Velasquez C3, Bustos J3, Arteaga A2,1Evidências - Kantar Health, São Paulo, Brazil, 2Grünenthal, Ciudad de México, Mexico, 3Grünenthal, Bogotá, Colombia ESTUDIO DE COSTO EFECTIVIDAD DEL FACTOR DE COAGULACIÓN RECOMBINANTE IX UNIDO A PROTEINA FC PARA EL TRATAMIENTO DE LA HEMOFILIA B EN CHILE Balmaceda C1, Vargas C1, Rodriguez F2, Rojas R1, Espinoza MA3,1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad San Sebastián, Santiago, Chile, 3e Investigador Visitante Honorario, Centro para la Economía de Salud, Universidad de York, York, UK
SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient Preference Studies PSY33 L12
PSY34 L13
PSY35 L14
PSY36 L15
PSY37 L16
PSY38 L17
HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PLAQUE PSORIASIS PATIENTS IN BRAZIL Lopes N1, Gontijo B2, Romiti R3, Santana PK4, Machado P1,1Novartis Biociências SA, Sao Paulo, Brazil, 2Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil, 3Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil, 4Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil WORK PRODUCTIVITY IN BRAZILIAN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Lopes N1, Antonio JR2, Fabricio L3, Azulay-Abulafia L4, Dias LL5, Pertel P6,1Novartis Biociências SA, Sao Paulo, Brazil, 2Fundação Faculdade Regional de Medicina de São José do Rio Preto, Sao Jose do Rio Preto, Brazil, 3Hospital Universitário Evangélico de Curitiba,, Curitiba, Brazil, 4Instituto de Dermatologia e Estética do Rio de Janeiro (IDERJ), Rio de Janeiro, Brazil, 5ANOVA, Rio de Janeiro, Brazil, 6Novartis Biociencias SA, Sao Paulo, Brazil TREATMENT SATISFACTION AMONG PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN BRAZIL Lopes N1, Suarez R. M2, Sabbag CY3, Kobata CM4, Takemoto MS5, Pertel P6,1Novartis Biociências SA, Sao Paulo, Brazil, 2Hospital do Servidor Público Municipal, Sao Paulo, Brazil, 3Centro Paulista de Investigação Clínica e Serviços (CEPIC), Sao Paulo, Brazil, 4Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil, 5ANOVA, Rio de Janeiro, Brazil, 6Novartis Biociencias SA, Sao Paulo, Brazil IXEKIZUMAB TREATMENT LEADS TO EARLY RESOLUTION OF BOTHERSOME SYMPTOMS VERSUS USTEKINUMAB Burge RT1, Papadimitropoulos M2, Henneges C3, Garcia EG4, Romiti R5,1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 3Eli Lilly and Company, Bad Homburg, Germany, 4Eli Lilly and Company, Mexico City, Mexico, 5Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil IXEKIZUMAB TREATMENT LEADS TO EARLY IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE VERSUS USTEKINUMAB Burge RT1, Papadimitropoulos M2, Henneges C3, Garcia EG4, Romiti R5,1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 3Eli Lilly and Company, Bad Homburg, Germany, 4Eli Lilly and Company, Mexico City, Mexico, 5Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil EPIDEMIOLOGY OF PHYSICIAN-DIAGNOSED NEUROPATHIC PAIN IN BRAZIL
22
PSY39 L18
PSY40 M1
PSY41 M2
PSY42 M3
PSY43 M4
Udall M1, Kudel I2, Cappelleri JC3, Sadosky A1, Concialdi K2, Parsons B1, Hlavacek P1, Hopps M1, Salomon P4, DiBonaventura M5, Clark P6, Garcia JB7,1Pfizer Inc., New York, NY, USA, 2Kantar Health, New York, NY, USA, 3Pfizer Inc., Groton, CT, USA, 4Pfizer Inc., Bosques de las Lomas, Mexico, 5Ipsos Healthcare, New York, NY, USA, 6Hospital Infanti de México, Cuauhtémoc, Mexico, 7University of Maranhão, São Luís, Brazil DELAYED BIOLOGIC SWITCHING AMONG PSORIATIC ARTHRITIS (PSA) PATIENTS MAY RESULT IN POOR HEALTH-RELATED QUALITY OF LIFE: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA Ranza R1, Alten R2, Strand V3, Sullivan E4, Blackburn S4, Tian H5, Gandhi K5, Jugl SM6, Conaghan PG7,1Teaching Hospital Universidade Federal Uberlandia, Uberlandia, Brazil, 2Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3Stanford University, Stanford, CA, USA, 4Adelphi Real World, Bollington, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7University of Leeds, Leeds, UK DELAYED BIOLOGIC SWITCHING AMONG ANKYLOSING SPONDYLITIS (AS) PATIENTS MAY RESULT IN POOR HEALTH- RELATED QUALITY OF LIFE: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA Pereira I1, Alten R2, Conaghan PG3, Strand V4, Sullivan E5, Blackburn S5, Tian H6, Gandhi K6, Jugl SM7, Deodhar A8,1University of Southern Santa Catarina-UNISUL, Florianópolis-SC, Brazil, 2Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3University of Leeds, Leeds, UK, 4Stanford University, Stanford, CA, USA, 5Adelphi Real World, Bollington, UK, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland, 8Oregon Health & Science University, Portland, OR, USA PSORIATIC ARTHRITIS LIMITS PATIENTS’ ABILITY TO CONTRIBUTE TO SOCIETY AS PART OF THE WORKFORCE: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA Scheinberg M1, Conaghan PG2, Alten R3, Sullivan E4, Blackburn S4, Tian H5, Gandhi K5, Jugl SM6, Strand V7,1Hospital AACD, Sao Paulo, Brazil, 2University of Leeds, Leeds, UK, 3Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 4Adelphi Real World, Bollington, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7Stanford University, Stanford, CA, USA ANKYLOSING SPONDYLITIS LIMITS PATIENTS’ ABILITY TO CONTRIBUTE TO SOCIETY AS PART OF THE WORKFORCE: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA Deodhar A1, Conaghan PG2, Alten R3, Sullivan E4, Blackburn S4, Tian H5, Gandhi K5, Jugl SM6, Strand V7,1Oregon Health & Science University, Portland, OR, USA, 2University of Leeds, Leeds, UK, 3Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 4Adelphi Real World, Bollington, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7Stanford University, Stanford, CA, USA IMPACTO DEL ÍNDICE DE MASA CORPORAL EN LA SALUD AUTOPERCIBIDA: RESULTADOS DE LA ENCUESTA NACIONAL DE SALUD DE CHILE 2016-2017 Monsalves mJ1, Duran D1, Aubert J1, Rosso F2, Lopez D2, Zarate V1,1Universidad San Sebastián, Santiago, Chile, 2ministerio de salud de chile, Santiago, Chile
SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies PSY44 M5
PSY45 M6
PSY46 M7
ELASTICIDAD PRECIO DE LA DEMANDA PARA EXPLORAR MEDIDAS IMPOSITIVAS QUE DESALIENTEN EL CONSUMO DE BEBIDAS AZUCARADAS Y CONTRIBUYAN A PREVENIR OBESIDAD Y DIABETES TIPO II. Mosqueira NR,Knowlege and Development, Lima, Peru TRATAMENTO CLÍNICO DE OBESIDADE ATRAVÉS DE INTERNAÇÕES CLÍNICAS EM SPA: IMPACTO ECONÔMICO DA JUDICIALIZAÇÃO Moraes Z, Castro AP, Pegoretti Rosa B,Evidencias - Kantar Health, Campinas, Brazil APPROPRIATE ANKYLOSING SPONDYLITIS (AS) TREATMENT IS DELAYED FOR YEARS: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA Pinheiro M1, Strand V2, Alten R3, Conaghan PG4, Sullivan E5, Blackburn S5, Tian H6, Gandhi K6, Jugl SM7, Deodhar A8,1Federal University of Sao Paulo (Unifesp/ EPM), Sao Paulo, Brazil, 2Stanford University, Stanford, CA, USA, 3Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 4University of Leeds, Leeds, UK, 5Adelphi Real World, Bollington, UK, 6Novartis
23
PSY47 M8
PSY48 M9
Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland, 8Oregon Health & Science University, Portland, OR, USA APPROPRIATE PSORIATIC ARTHRITIS TREATMENT IS DELAYED FOR YEARS: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA Azevedo VF1, Conaghan PG2, Strand V3, Sullivan E4, Blackburn S4, Tian H5, Gandhi K5, Jugl SM6, Alten R7,1Federal University of Paraná, Curitiba, Brazil, 2University of Leeds, Leeds, UK, 3Stanford University, Stanford, CA, USA, 4Adelphi Real World, Bollington, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany TASAS DE HOSPITALIZACIÓN DE LOS PACIENTES CON DEFECTOS DE LA COAGULACIÓN (DEMANDA Y PROFILAXIS) EN UNA ASEGURADORA COLOMBIANA Romero Prada ME1, Roa Cardenas NC2, Huerfano LM1, Cruz AM3, Barrios E4, Marino C5,1Fundación Salutia, Bogotá, Colombia, 2Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, 3Coomeva EPS, Cali, Colombia, 4Coomeva Group, Cali, Colombia, 5Coomeva, Bogotá, Colombia
URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies PUK1 M10 EFFICACY OF ANTIOXIDANT SUPPLEMENTS ON PREVENTION AND AMELIORATION OF DIABETES-INDUCED NEPHROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Mukherjee A, Kandhare AD, Bodhankar SL,Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India PUK2 M11 EFFICACY OF ANTIOXIDANT SUPPLEMENTS ON PREVENTION AND AMELIORATION OF CISPLATIN-INDUCED NEPHROTOXICITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Kandhare AD, Mukherjee A,Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India URINARY/KIDNEY DISORDERS - Cost Studies PUK3 M12 COST ANALYSIS OF PRE-DIALYSIS: A MODEL IN THE BRAZILIAN CONTEXT Moraes Jr CS, Colugnati F, Bastos MG,Federal University of Juiz de Fora, Juiz de Fora, Brazil PUK4 M13 ESTUDIO DE COSTO- CONSECUENCIA DE DARBEPOETINA ALFA PARA EL TRATAMIENTO DE ANEMIA SINTOMÁTICA DERIVADA DE LA ENFERMEDAD RENAL CRÓNICA EN COLOMBIA Vargas-Valencia J1, Garcia Perlaza J2, Perez M2,1Econopharma Consulting, Mexico, Mexico, 2AMGEN, Bogotá, Colombia PUK5 N1 COST EFFECTIVENESS OF PERITONEAL DIALYSIS PROVISION FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE FROM PUBLIC HEALTH PERSPECTIVE IN CHILE Rojas R1, Vargas C1, Balmaceda C1, Espinoza MA2,1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2e Investigador Visitante Honorario, Centro para la Economía de Salud, Universidad de York, York, UK PUK6 N2 A COST-EFFECTIVENESS ANALYSIS OF TACROLIMUS XL IN COMPARISON TO GENERIC TACROLIMUS FROM THE PUBLIC HEALTHCARE SECTOR IN MEXICO Anaya P1, de Anda JA2, Salazar A3, Braun S4,1IMS Health, México, D.F., Mexico, 2IMS Health, México, D.F., IL, USA, 3Janssen Mexico, Mexico City, IL, USA, 4Astellas Pharma US, Inc., Northbrook, IL, USA URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes & Patient Preference Studies PUK7 N3
PUK8 N4
THE EQUIVALENCE BETWEEN THE MALAY AND U.S. ENGLISH VERSIONS OF RAND 36-ITEM HEALTH SURVEY 1.0 Kharshid A1, Syed Sulaiman SA1, Aly A1, Aldraimly M1, Almaghrabi N2,1Department of Clinical Pharmacy, Faculty of Pharmaceutical science, Universiti Sains Malaysia, penang, Malaysia, 2King Abdulaziz Medical City, Riyadh, Saudi Arabia LOWER HEMOGLOBIN (HB) LEVELS NEGATIVELY IMPACT QUALITY OF LIFE (QOL) AMONG PERITONEAL DIALYSIS (PD) PATIENTS: RESULTS FROM A NATIONAL REPRESENTATIVE COHORT STUDY IN BRAZIL (BRAZPD) Bragg-Gresham J1, Guedim de Campos L2, Han Y1, Moraes TP2, Figueiredo AE2, Barretti P3, Balkrishnan R4, Saran R1, Pecoits-Filho R2,1University of Michigan School of Medicine, Ann Arbor,
24
PUK9 N5
MI, USA, 2Pontifícia Universidade Católica do Paraná, Curitiba, Brazil, 3São Paulo State University, São Paulo, Brazil, 4University of Virginia School of Medicine, Charlottesville, VA, USA EVALUATION OF HEALTH-RELATED QUALITY OF LIFE AMONG MALAYSIAN NON DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE PATIENTS Aly A1, Kharshid A1, Syed Sulaiman SA1, Lamfon N2, Alshaer M2,1Department of Clinical Pharmacy, Faculty of Pharmaceutical science, Universiti Sains Malaysia, penang, Malaysia, 2King Abdulaziz Medical City, Riyadh, Saudi Arabia
URINARY/KIDNEY DISORDERS - Health Care Use & Policy Studies PUK10 N6
PUK11 N7
PATIENTS WITH HIGH COMORBIDITY AND TRANSITIONING TO DIALYSIS AT HIGH RISK OF SUBOPTIMAL ANTIHYPERTENSIVE MEDICATION PRESCRIPTION USE: RESULTS FROM A BRAZILIAN NATIONAL COHORT (BRAZPD) OF PERITONEAL DIALYSIS Balkrishnan R1, Han Y2, Guedim de Campos L3, Saran R2, Bragg-Gresham J2, Pecoits-Filho R3,1University of Virginia School of Medicine, Charlottesville, VA, USA, 2University of Michigan School of Medicine, Ann Arbor, MI, USA, 3Pontifícia Universidade Católica do Paraná, Curitiba, Brazil GEOGRAFIA DO GASTO PÚBLICO COM NEFROLOGIA NO BRASIL 2013 A 2016. Moraes Jr CS, Colugnati F, Bastos MG,Federal University of Juiz de Fora, Juiz de Fora, Brazil
25
